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 i 
ABSTRACT 
 
Protein S-glutathionylation (PGLU) reactions in mitochondria, catalyzed by glutaredoxin-
2 (Grx2), have been shown to regulate carbon catabolism, oxidative phosphorylation and reactive 
oxygen species (ROS) production in response to changes in redox balance. In addition, deletion of 
the Grx2 gene increases phosphorylating respiration and proton leaks in muscle tissue which 
correlates with decreased fat mass and body weight. However, whether or not manipulation of 
Grx2 levels protects from diet-induced obesity (DIO) has never been investigated. Our objective 
was to examine the potential anti-obesity effect associated with the absence of the Grx2 gene in 
C57BL/6N mice. Here, we demonstrate that Grx2+/- mice were protected from diet-induced weight 
gain and obesity-related disorders associated with increases in mitochondrial respiration attributed, 
in part, to increased leaks through uncoupling protein-3. Collectively, our results demonstrate that 
S-glutathionylation reactions are integral for regulating muscle metabolism and fat combustion 
and reveal that manipulation of Grx2 signaling may serve as an exercise mimetic that can be 
employed to treat/prevent DIO.  
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Chapter 1: Introduction 
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1.1 Energy Metabolism  
Mitochondria are referred to as the powerhouses of mammalian cells for good reason. 
Indeed, these double-membrane organelles are required to satisfy most of the cell’s energy 
demands, which is achieved by oxidizing fuel (e.g. carbon) to make ATP (1)(1). The evolution of 
multicellular organisms was driven, in part, by the capacity of mitochondria to conserve and 
produce large amounts of energy. The upshot of this feature was the genesis of complex lifeforms 
like mammals. ATP is required to drive most physiological functions ranging from heartbeat and 
locomotion to immune cell function and xenobiotic detoxification (2). This also includes mediating 
cell signals emanating from extracellular hormones through the phosphorylation of proteins or 
production of cyclic-AMP (cAMP). At its core, mitochondrial ATP production relies on the 
production of a protonmotive force (PMF) across the mitochondrial inner membrane (MIM). This 
process begins when different forms of carbon (e.g. sugars, fats, and amino acids) are converted 
to Krebs cycle intermediates. The electrons released by metabolizing intermediates in the Krebs 
cycle are transported to the electron transport chain (ETC) and used to reduce the terminal acceptor 
molecular oxygen (O2) to H2O. Movement of these electrons through the chain is coupled to the 
pumping of protons into the intermembrane space (IMS), creating a PMF that is then used to make 
ATP. However, it is not the ETC and carbon oxidizing enzymes that imbued mitochondria with 
the capacity to generate large quantities of ATP. Rather, it is the highly folded MIM, which greatly 
increased the energy transducing surface area of mitochondria (2). 
1.1.1 Glycolysis 
  The aerobic oxidation of monosaccharides begins with glycolysis, a 10-step process that 
transforms and breaks down glucose molecules to generate two pyruvate and two ATP molecules. 
The process is outlined in (Figure 1.1).  Pyruvate then enters the Krebs cycle where it undergoes 
 3 
further oxidation. The glycolytic breakdown of monosaccharides can be subdivided into two 
different steps. The first step is called the “preparatory phase”, where 2 ATP molecules are used 
to prime the hexose ring for electron extraction and degradation. The first step of the preparatory 
phase is initiated by hexokinase, which, in the presence of Mg2+, expends ATP to phosphorylate 
glucose on the C6 position, yielding glucose-6-phosphate. Notably, there are four different 
hexokinase isozymes including glucokinase, which is found in hepatocytes and pancreatic β-cells 
and is required for the maintenance of blood glucose levels. Myocytes contain hexokinase isoforms 
I and II, which are both allosterically inhibited by glucose-6-phosphate. Phosphohexose isomerase 
then mediates conversion of glucose-6-phosphate to fructose-6-phosphate in the presence of Mg2+. 
This product is then phosphorylated a second time by phosphofructokinase-1, generating fructose 
1,6-bisphosphate at the expense of 1 molecule of ATP (3). Aldolase then splits fructose 1,6-
bisphosphate into two 3-carbon molecules, 1 glyceraldehyde 3-phosphate, and dihydroxyacetone 
phosphate.  In the final step of the preparatory phase, the dihydroxyacetone phosphate molecule is 
converted to glyceraldehyde 3-phosphate by the action of trisphosphate isomerase (3).  
 Next, the two glyceraldehyde-3-phosphate molecules are used to drive the substrate-level 
phosphorylation of ADP, forming ATP, via the second part of glycolysis. First, glyceraldehyde 3-
phosphate is oxidized and phosphorylated to 1,3 bisphosphoglycerate by the glyceraldehyde-3-
phosphate dehydrogenase complex (GADPH) (4). Electrons released by this process are 
transferred to nicotinamide adenine dinucleotide (NAD+) generating an NADH. After its 
production, the hydride from NADH can be transferred to oxaloacetate in the cytosol forming 
malate, which is then taken up by mitochondria through the malate-aspartate shuttle.  
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Figure 1.1: Glycolysis  
Carbon is denoted by black rings. 
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Alternatively, the NADH formed in the cytosol by glycolysis can be used to reduce pyruvate to 
lactate by lactate dehydrogenase when cells are deprived of O2. 1,3-bisphosphoglycerate is a mixed 
acid-anhydride which encourages nucleophilic attack of the terminal phosphate by ADP molecule, 
resulting in the formation of ATP and 3-phosphoglycerate, a reaction catalyzed by 
phosphoglycerate kinase (1). Steps 8 and 9 comprise an intramolecular rearrangement of the 
phosphate bond, and a dehydration reaction catalyzed by phosphoglycerate mutase and enolase, 
respectively, generating the high energy molecule, phosphoenolpyruvate. The final step occurs in 
2 parts. Pyruvate kinase catalyzes the transfer of the phosphate group from phosphoenolpyruvate 
to ADP generating another molecule of ATP, as well as an enolate form of pyruvate, which is 
further reduced to the keto form through the electrophilic addition of a proton (H+). Once formed, 
pyruvate is either converted to lactate or taken up by mitochondria where it undergoes further 
oxidation. The net reaction for glycolysis is as follows:  
Equation 1.1: Glycolysis 
Glucose + 2 NAD+ + 2 ADP + 2 Pi → 2 pyruvate + 2 ATP + 2 NADH + 2 H+ 
1.1.2 Krebs Cycle 
 The Krebs cycle acts as a central point where carbons from multiple sources converge for 
the extraction and transfer of electrons to the ETC (5). For instance, pyruvate yielded from 
glycolysis is oxidized further by the concerted action of Krebs cycle enzymes. This begins when 
pyruvate carrier translocates pyruvate into the matrix of mitochondria (Figure 1.2). This is driven 
by the Gibbs free energy stored in the PMF, which couples the energetically unfavorable transport 
of pyruvate into the matrix. Pyruvate is then converted to acetyl CoA by the action of the pyruvate 
dehydrogenase complex (PDH). PDH is a 3-subunit enzyme complex that carries out the oxidative 
decarboxylation of pyruvate generating acetyl-CoA, NADH, and CO2. The E1 subunit of PDH, 
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pyruvate decarboxylase, decarboxylates pyruvate, transferring the acetyl group to thiamine 
pyrophosphate. The acetyl group is then transferred to lipoic acid of the E2 subunit, dihydrolipoyl 
transacetylase. The prosthetic lipoic acid arm of the E2 subunit is covalently attached but swings 
freely allowing the acetyl group to be transferred to coenzyme A (CoASH) generating acetyl-CoA. 
This reduction-oxidation reaction leaves the lipoic acid group in a reduced, inactive state. The E3 
subunit, dihydrolipoyl dehydrogenase, restores the active lipoic acid prosthetic group by 
transferring its electrons to FAD. Finally, the FAD prosthetic group is restored by transferring 
electrons to NAD+ generating NADH (6). It is important to point out that acetyl-CoA sits at a 
metabolic intersection for oxidative metabolism. Indeed, the oxidation of fatty acids (FA) by 
mitochondria also generates acetyl-CoA. Various amino acids including alanine, cysteine, glycine, 
and tryptophan also yield acetyl-CoA (1). With this in mind, disparate sources of carbon that are 
catabolized for mitochondrial ATP production in mitochondria are first converted to common 
intermediates that can then undergo further oxidation by the Krebs cycle.   
 Pyruvate is also required to prime the Krebs cycle through the production of oxaloacetate. 
This is achieved by pyruvate carboxylase, which carboxylates pyruvate using ATP and bicarbonate 
in the presence of biotin. Next, acetyl-CoA enters the Krebs cycle through condensation with 
oxaloacetate, a reaction mediated by citrate synthase, which generates citrate. There is a large 
negative free energy associated with this condensation reaction that is essential for the progress of 
the cycle (1). In the next step, citrate is isomerized to isocitrate through a cis-aconitate intermediate 
by the enzyme aconitase (1). Isocitrate is then oxidized by isocitrate dehydrogenase (IDH), 
generating 2-oxoglutarate and CO2. The evolution of CO2 following isocitrate oxidation is coupled 
with the production of NADH. It is important to note that mitochondria contain two IDH isozymes. 
IDH1 is required to generate NADH during fuel combustion by the Krebs cycle (7).   
 7 
 
  
Figure 1.2: The Krebs cycle 
The enzymes involved in carbon conversion are as follows: 1- citrate synthase, 2- aconitase, 3- 
isocitrate dehydrogenase, 4- 2-oxoglutarate dehydrogenase, 5- succinyl CoA synthase, 6- 
succinate dehydrogenase, 7- fumarase, 8- malate dehydrogenase.  
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IDH2, on the other hand, couples isocitrate oxidation to the genesis of NADPH, a critical factor 
required for antioxidant defenses. The next step is catalyzed by the 2-oxoglutarate dehydrogenase 
complex (OGDH), a structural analog to the PDH complex discussed earlier. OGDH uses E3 and 
E2 subunits that are highly homologous to the PDH equivalents (8). The difference between 
OGDH and PDH lies in the E1 and E2 subunits, which are named 2-oxoglutarate decarboxylase 
(E1) and dihydrolipoamide:succinyl-CoA transferase (E2), respectively. Decarboxylation of 2-
oxoglutarate generates succinyl-CoA, CO2 and NADH. Various amino acids can also enter into 
the Krebs cycle at the level of 2-oxoglutarate. Indeed, the oxidation of all amino acids by the Krebs 
cycle relies on aminotransferases, which produce 2-oxoglutarate from reversible deamination 
reactions. Hydrolysis of succinyl-CoA is mediated by succinyl-CoA synthase (SCS) generating 
succinate and GTP/ATP (note that production of either GTP or ATP depends on the SCS isoform) 
(9). The next step is catalyzed by the succinate dehydrogenase (SDH), also known as complex II. 
SDH is embedded in the inner leaflet of the MIM and therefore, electrons released from the 
oxidation of succinate to fumarate are transferred directly to the UQ pool. Since UQ serves as an 
electron carrier in the respiratory chain, SDH directly links the Krebs cycle and the ETC. The 
hydration of fumarate by fumarase (FUM) generates malate which is finally oxidized by malate 
dehydrogenase (MDH) for the generation of oxaloacetate which re-enters the cycle (2). This final 
stage also produces the electron carrier NADH (1).  
1.1.3 Lipid metabolism and the  oxidation of fatty acids 
 Fatty acids used for the production of ATP can either be derived from dietary lipids or 
lipids formed by de novo lipogenesis. Absorption of dietary lipids begins when they are emulsified 
by bile acids in the small intestine. This generates micelles that contain a variety of lipids, including 
triacylglycerol (TAG), cholesterol, and phospholipids, that are imported into enterocytes (10). 
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These lipids are then processed further inside enterocytes and packaged into chylomicrons along 
with apolipoproteins, which are then secreted into the lymph (1, 11). De novo lipogenesis, on the 
other hand, primarily occurs in hepatocytes where amino acids, glucose and other 
monosaccharides are used for lipid biosynthesis (12). Triglycerides formed by lipogenesis are then 
packaged into very low-density lipoproteins (VLDL) for transport around the body as outlined in 
Figure 1.3.  
Transport of chylomicrons or VLDL to energy-requiring cells, like myocytes in skeletal 
muscle. TAG in Chylomicrons and VLDL are degraded by lipoprotein lipases to give fatty acids 
which are then taken up by myocytes. Fatty acids are then taken up by mitochondria by β-oxidation 
(also called fatty acid oxidation). Palmitate (long chain fatty acid) is the most abundant fatty acid 
found in the human body (13) and is thus the main substrate for fatty acid oxidation. However, it 
is important to point out that mitochondria can also oxidize short and medium-chain fatty acids, 
which either originate from dietary sources or are produced by palmitate oxidation. Fatty acid 
oxidation is initiated by first modifying palmitate (or other fatty acyl molecules) with CoASH 
generating palmitoyl-CoA, a reaction catalyzed by acyl-CoA synthetase in the presence of ATP 
(14). Carnitine palmitoyltransferase 1 (CPT1) then catalyzes the removal of CoASH, replacing it 
with L-carnitine (15). This allows mitochondrial import of fatty acyl-carnitine by the action of the 
acyl-carnitine/carnitine transporter (CACT) (16). Note that CACT is an antiporter that couples the 
uptake of acyl-carnitine to the export of L-carnitine. Once delivered to the matrix of the 
mitochondria, fatty acyl-CoA is regenerated in a transfer reaction mediated by the MIM associated 
isozyme carnitine palmitoyltransferase 2 (CPT2) (15). The fatty acyl-CoA units are now primed 
for  oxidation.  
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Figure 1.3: Lipid transport  
Dietary lipids are converted to chylomicrons for fatty acid delivery to liver and adipose tissue 
for storage as well as muscle tissue to meet energy demands. The liver stores fatty acids as 
triglycerides, which are then packaged into VLDL for release into circulation.  
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 Fatty acid oxidation in the matrix of mitochondria is initiated by acyl CoA dehydrogenase, 
which oxidizes palmitoyl-CoA (and other acyl-CoA molecules) introducing a double bond in a 
trans configuration between the  and  carbon of the fatty acid chain (17). The two electrons 
yielded from palmitoyl-CoA oxidation reduce a flavin adenine dinucleotide (FAD) prosthetic 
group to FADH2. These electrons are then transferred to electron-transferring 
flavoprotein:ubiquinone oxidoreductase (ETF-QO), an FAD-containing enzyme that reduces UQ 
in the respiratory chain. The second reaction, mediated by enoyl hydratase, is a hydration reaction 
which adds H2O across the newly forged double bond. Enoyl hydratase is incapable of acting on 
the naturally occurring cis double bonds present in unsaturated fatty acids. For this reason, 
auxiliary isomerase and reductase enzymes generate double bonds in the trans configuration to 
facilitate an unimpeded  oxidation cycle in mono and poly-unsaturated fatty acids (18). Beta-
hydroxy palmitoyl-CoA is then oxidized by β-hydroxyacyl-CoA dehydrogenase, generating β-
keto palmitoyl-CoA and NADH. Finally, acyl-CoA acetyltransferase catalyzes the transfer of the 
2 carboxyl terminal carbons of the recently generated -ketoacyl-CoA to a free CoA generating 
acetyl CoA and a new acyl-CoA that will re-enter the cycle. This process produces 1 FADH2, 1 
NADH, and 1 Acetyl CoA per 2 carbons of the fatty acid chain. Electrons transferred to FAD 
immediately enter the ETC by subsequent reductions of electron transfer protein (ETF) followed 
by ETF-QO and finally the Ubiquinone (UQ) pool (2). Electrons transferred to NADH enter the 
ETC at the level of complex I, and acetyl CoA enters the Krebs cycle, discussed later.   
1.1.4 Oxidative phosphorylation 
 Oxidative phosphorylation represents the final stage of energy extraction from common 
carbon intermediates for the genesis of ATP. This process is outlined in Figure 1.4. Electrons can 
enter the ETC at either complex I through the oxidation of NADH or can be fed directly into the 
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chain via the reduction of UQ to ubiquinol (UQH2) (e.g. during succinate oxidation). NADH acts 
as an efficient electron carrier, shuttling electrons donated from crucial enzymes of the glycolytic 
pathway,  oxidation, the Krebs cycle, and other metabolic sources. These electrons enter the ETC 
at NADH-UQ oxidoreductase (complex I). Complex I is the largest of the 4 complexes of the ETC 
with 14 core proteins and 31-32 accessory proteins (2). The subunits of complex I form a 
distinctive L-shape that consists of 3 major modules; N, Q and P modules. The N module consists 
of 7 of the 14 core proteins; NDUFV1, NDUFV2, NDUFS1, NDUFS2, NDUFS3, NDUFS7, and 
NDUFS8 (2). This module protrudes into the matrix of the mitochondria and contains a flavin 
mononucleotide (FMN) prosthetic group and 7 Fe-S clusters (2). The FMN of the N module is the 
site for NADH oxidation. Electrons extracted from NADH are transferred to the FMN prosthetic 
group and then through the 7 Fe-S clusters, reducing UQ to UQH2 in the Q module, which sits at 
the junction between the N and P modules. The P module contains the core proteins ND1, ND2, 
ND3, ND4, ND4L, ND5 and ND6. It is a hydrophobic domain embedded in the MIM and is 
responsible for pumping 4 protons across the MIM for each NADH oxidized (2 electrons 
transferred) (2). 
As previously discussed, complex II also feeds electrons into the ETC from succinate (2). 
Electron transfer in this complex is mediated by FAD and 3 Iron-sulfur (Fe-S) clusters. Electrons 
pass from succinate to FAD, and subsequently through the 3 Fe-S clusters to reduce UQ to UQH2 
in the UQ binding site in the MIM. Complex II is incapable of transferring electrons across the 
MIM; since the potential for the succinate/fumarate and UQH2/UQ pairs are very close, the Gibbs 
free energy change for e- transfer is almost 0. This contrasts with the other complexes where 
electron flow through their prosthetic groups is energetically favorable and thus coupled to the 
pumping of protons into the IMS. Similarly, electrons are transferred to the UQ pool by the 
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enzymes ETF-QO, and GAPDH discussed earlier, as well as dihydroorotate dehydrogenase 
(DHODH) (19–22). These three enzymes associate with the outer leaflet of the MIM in contrast 
to complex II.  
The next step is catalyzed by the activity of ubiquinone: cytochrome c oxidoreductase 
(complex III). Complex III catalyzes the transfer of electrons from the UQ pool to cytochrome c 
through a process first proposed by Peter D. Mitchell known as the Q-cycle (23). Complex III 
contains 2 UQ binding sites, QP and QN and 2 B-type haeme, BL and BH. QP and BL are located 
near the cytosolic side of the MIM while QN and BH are located on the matrix side of the MIM 
(24). Also, associated with the outer leaflet of the MIM is the Rieske protein which contains an 
Fe-S cluster and interacts with cytochrome c1 (cyt c1) (24). Electron transfer and proton 
translocation across the MIM by the Q-cycle occur in multiple steps. First UQH2 binds the QP site. 
Two single-electron transfer reactions occur. One electron is passed to cyt c1 through the Fe-S 
cluster of the Rieske protein. This generates a semiquinone radical (UQ•-) in the QP site and 
releases 2 protons to the cytosolic side of the MIM (23). The second electron is passed to the 
adjacent BL generating UQ. In the next step, the electron bound to BL is transferred to BH on the 
matrix side of the MIM. Free UQ binds to the adjacent QN site and is reduced to UQ•
-. This UQ•- 
radical is stabilized by the BH haem while a second UQH2 enters the QP site near the cytosolic side 
of the MIM. A second round of electrons then transfers 2 more protons to the cytosol, one more 
electron to cyt c1 and finally a second electron to the UQ•
- radical bound to the QN site. Two protons 
are taken up from the matrix to reduce UQ•- to UQH2 and the cycle can begin again (23).  
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Figure 1.4:  Nutrient oxidation. 
Electrons from multiple carbon intermediates are transported to the ETC where the movement 
of these electrons in an energetically favorable fashion is coupled to the pumping of protons 
across the mitochondrial inner membrane. The PMF is then utilized by complex V for the 
generation of ATP. The 12 known sites of ROS production are indicated in red text. Enzymes 
contributing to acetyl CoA production include pyruvate dehydrogenase (PDH), branched chain 
keto acid dehydrogenase (BCKDH), oxoadipic acid dehydrogenase (OADH) and acetyl-CoA 
acyltransferase of β oxidation. Enzymes contributing electrons to the QH pool include, complex 
I, complex II, glycerate 3-phosphate dehydrogenase (G3PDH), dihydroorotate dehydrogenase 
(DHODH), proline dehydrogenase (ProDH), electron transfer flavoprotein:ubiquinone 
oxidoreductase (ETFQO). Electron flow from complex III to Complex IV is mediated by 
cytochrome c (Cyt c) and proton return to the matrix is coupled to ATP generation by the F1Fo 
ATP synthase. 
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 Electrons are transferred from cyt c1 to cytochrome c (cyt c), which binds to cytochrome 
c1 via electrostatic interactions on the outer leaflet of the MIM. Once it accepts an electron, it 
quickly diffuses to cytochrome c oxidase (complex IV) (25).  Electrons are transferred from cyt c 
to CuA, a copper sulfur center in a subunit of complex IV that extends lightly into the cytosol.  
Electrons then flow through 2 haem groups haem a and a3. O2 is bound at haem a3 and reduced to 
2 molecules of H2O after accepting four electrons. This process pumps 4 protons across the MIM 
for every H2O molecule produced (26).  
For every 2 electrons traveling through the ETC, 4 protons are pumped by complex I, 2 
protons by complex III and 4 by complex IV. NADH oxidation drives the translocation of ~10 
protons into the intermembrane space.  By contrast, electron donors that by-pass complex I, 
donating electrons directly to the UQ pool (e.g. oxidation of succinate by complex II) pump only 
6 protons across the MIM (27). The movement of protons into the intermembrane space establishes 
a transmembrane electrochemical gradient called the PMF. The PMF is comprised of a membrane 
potential (m), the electric component, and a proton concentration gradient (pHm), the chemical 
component, with the latter making a smaller contribution to the PMF since the potential energy for 
m is much larger than pHm (28). The PMF acts as the driving force utilized by complex V for 
the generation of ATP and generally ranges between 180 - 220 mV (29). The PMF, however, is 
not exhaustively consumed by ATP production since cells have found utility in this imbalance for 
transport and antioxidant defense. For instance, various transport proteins embedded in the MIM, 
collectively referred to as the solute anion carrier superfamily, couple the selective uptake of 
charged or hydrophilic molecules to the proton gradient. Pyruvate delivery to the matrix of the 
mitochondria is not energetically favorable due to the similar charges of pyruvate and the matrix. 
As a result, the mitochondrial pyruvate carrier is a proton-pyruvate symporter which uses the 
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proton gradient to supply energy for active transport (30). For antioxidant defenses, the PMF is 
used by nicotinamide nucleotide transhydrogenase to drive the transfer of a proton from NADH to 
NADP+ generating NADPH for reduction of antioxidant defense systems, discussed later (31). The 
PMF can also be siphoned by what are known as uncoupling proteins, discussed later in greater 
detail. These proteins are so called because they allow an alternative path for protons across the 
MIM bypassing complex V, “uncoupling” ATP generation from the pumping of protons across 
the MIM (32). All organisms on our planet rely on the genesis of electrochemical gradients, which 
is why it is now thought that the PMF (and other gradients), rather than ATP, is thought to be the 
universal energy currency (33). 
Complex V consists of two subcomplexes arranged in the MIM as demonstrated in Figure 
1.5. The hydrophobic Fo subcomplex consists of an a subunit, two b subunits and 8-14 c subunits. 
The number of c subunits is a debated topic and differs between mitochondria, thylakoids, and 
prokaryotes (34). The c subunits are arranged in a ring embedded in the MIM and provide the 
means for proton translocation. At the interface between the a subunit and the c-ring, are two half 
channels that are opened to the n and p sides of the MIM, denoted the entrance and exit channels, 
respectively (35). Alternate protonation, deprotonation of Arg61 of the c subunits result in 
movement of the c-ring encouraging interaction with the entrance and exit channels. This 
movement allows proton return through the MIM (35, 36). The a subunit remains stationary and 
is bound to the F1 complex by the b subunits. The water-soluble F1 complex consists of 3  and 3 
 subunits arranged in an alternating ring pattern surrounding a  subunit (37). The  subunit 
associates with b subunits of the Fo complex via a  subunit and associates with the center of the 
Fo c-ring. When isolated the F1 complex maintains ATPase activity but not ATP synthesizing 
activity (38).   
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Figure 1.5: The FoF1 ATP Synthase 
Proton return through channels in subunit a drives rotation of the c subunits resulting in rotation 
of the γ subunit within the α and β subunits that are anchored in place by attachment to the b 
subunits. This drives conformational changes that catalyze the phosphorylation of ADP 
generating ATP. 
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The PMF driven rotation of the c-ring drives the rotation of the  subunit which rotates within the 
stationary  ring resulting in conformational changes in the  and  subunits. Each rotation of 
the  ring results in 3 ATP molecules produced. This process is known as rotational catalysis and 
drives ATP synthesis through changes in affinity of the  and  subunits for ATP, ADP and 
inorganic phosphate (Pi) (39). The H
+/ATP ratio of the mammalian complex V is 8/3 since a single 
rotation of the c-ring results in one single rotation of the  ring (2).  
Electrons extracted from multiple dietary sources enter the ETC at a highly negative redox 
state through the oxidation of NADH or the direct reduction of the UQ pool. The movement of 
these electrons through the ETC is energetically favorable and is often perceived as moving in a 
“downhill fashion”, from a negative redox potential to a more positive one. The redox potential of 
the NADH/NAD+ pool is approximately -320 mV, while the redox potential of the H2O/O2 pair, 
the terminal electron acceptor, is approximately +820 mV (2). This process is coupled to the 
pumping of protons across the MIM generating a PMF utilized by the FoF1 ATP synthase (complex 
V) for the production of ATP. 
1.2 Reactive Oxygen Species 
Fuel combustion and the reduction of O2 by complex IV is not perfectly coupled to the 
genesis of ATP. At various points in the Krebs cycle and the respiratory chain, in addition to other 
nutrient-oxidizing enzymes, electrons can “spin-off” and prematurely react with O2 and form 
oxyradicals called reactive oxygen species (ROS). Mitochondria are the most important source of 
ROS in mammalian cells, a property attributed to the fact that their functions rely on fuel 
metabolism and redox reactions. Molecular oxygen contains two lone electrons with parallel spins 
in its outer most anti-bonding orbital (note that this feature also classifies O2 as a reactive oxygen 
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species). Therefore, O2 can only accept one electron at a time, resulting in the formation of several 
reactive intermediates such as superoxide (O2•
-), hydrogen peroxide (H2O2), and hydroxyl radical 
(OH●) before its full reduction to H2O. Superoxide is often considered the proximal ROS formed 
by mitochondria due to the fact that its production only requires the monovalent reduction of O2. 
However, it has now become clear that sites of production in mitochondria can produce a mixture 
of O2•
-
 and H2O2 (40). Most sites for ROS release in mitochondria are flavoproteins and the 
capacity of these sites to generate O2•
-
 and H2O2 is highly dependent on flavin chemistry and how 
it reacts with O2. Furthermore, recent estimates have found that H2O2, not O2•
-
, is the dominant 
ROS formed by sites of production.  However, O2•
-
 is formed by mitochondria nonetheless, which 
needs to be rapidly removed since it can disassemble Fe-S clusters at a rate of k = 107 M-1 s-1 (41, 
42). This is especially important for mitochondria since several Krebs cycle enzymes and 
respiratory chain complexes are dependent on Fe-S clusters for nutrient oxidation and electron 
transport. For this reason, mitochondria contain high amounts of superoxide dismutase (SOD), 
which quickly dismutates O2•
- to H2O2 at a rate of k = 1.8 x 10
9 M-1s-1. Mitochondria also contain 
two different SOD isoforms, SOD1 (copper and zinc-dependent) in the IMS, and SOD2 
(manganese-dependent) in the matrix, meaning that O2•
- formed on either side of the MIM can be 
rapidly removed (42). H2O2 concentrations range from 10
-7 – 10-9 M, while O2•- concentrations are 
much lower at around 10-10 – 10-12 (43, 44). As a result, H2O2 is the most abundant form of ROS 
produced. Hydrogen peroxide can irreversibly oxidize protein cysteine thiols and is considered a 
strong oxidant. However, due to high activation energy restraints, it reacts with few protein 
cysteine thiols and only becomes a danger to cells when its concentration is in the low millimolar 
range (45, 46). 
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As noted above, H2O2 weakly reacts with most cysteine thiols and O2
●- is a weak oxidant 
despite the fact it can react rapidly with Fe-S clusters. Superoxide and hydrogen peroxide become 
extremely dangerous to living systems in the presence of free Fe, which, through one electron 
transfer and homolytic cleavage reactions, can generate OH●. Hydroxyl radical generation occurs 
through H2O2 interactions with Fe
2+ known as Fenton reactions. Fe3+ can also catalyze OH● 
generation by transferring an electron from O2•
- to H2O2 through a Fe
2+ intermediate. This is known 
as a Haber-Weiss reaction:  
Equation 1.2: Haber-Weiss reaction 
Fe3+ + O2•
-       →    Fe2+ + O2   
Fe2+ + H2O2     →   OH●+ OH- + Fe3+ (Fenton reaction) 
O2•
-
 + H2O2      →   O2 + OH●+ OH- (in the presence of Fe2+/Fe3+) 
 
The volatile reactivity of OH● allows it to directly modify protein and nucleotides leading to 
protein oxidation and inactivation as well as dsDNA breaks and accelerated mutagenesis (46, 47). 
The generation of OH● can also lead to lipid peroxide initiation and propagation. Lipid peroxides 
are associated with a wide range of cellular dysfunction. They alter membrane fluidity and 
permeability and subsequently lead to protein and DNA modification as a result of by-products of 
their degradation (48–51) An additional danger lies in the generation of reactive nitrogen species 
through the interactions of NO and ROS (52–54). Peroxynitrite, for example, can lead to the 
oxidation as well as nitration of protein and DNA promoting cell cycle arrest or mutagenesis. The 
ensuing consequence of excessive mitochondrial ROS is programmed cell death to minimize 
damage caused to other cells or its progression to a cancerous state (53, 55).  
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Our collective understanding of the role of ROS has changed in recent decades due to new 
research revealing the hormetic relationship between mitochondrial ROS and the cell. Indeed, 
while high levels of ROS can be detrimental, as previously discussed, ROS at physiologically 
relevant levels are essential for normal cellular function and induce what has recently been coined 
as oxidative eustress (56). This term was created to differentiate between mitochondrial ROS 
associated with cellular damage (also called oxidative distress) and ROS levels that coordinate 
cellular processes including cellular adaptive response, cellular proliferation and growth, insulin 
signaling pathways, and T-cell activation (45, 57, 58).  In skeletal muscle, for example, low-level 
ROS production is required for normal muscle force production in skeletal muscle mitochondria. 
Increased ROS production during exercise initiates AMPK mediated upregulation of GLUT4 
membrane translocation, inducing insulin-independent glucose import (59). Low-level ROS 
production in skeletal muscle also modulates IGF-1 expression and signaling through regulation 
of the PI3K/Akt pathway (60). Finally, ROS production during exercise is also required for muscle 
growth and adaptation, increasing stress resistance in myofibers. However, overproduction of ROS 
in muscle can be damaging, leading to diminished muscle force generation and development of 
sarcopenia (61). In pancreatic beta cells, transient increases in glucose availability led to increased 
ROS production which modulated calcium mobility. This process was essential for glucose-
stimulated insulin secretion (62).  
The 12 known locations of ROS production have been extensively studied and reviewed 
by Martin D. Brand (63). The sites are subcategorized into the NADH/NAD+ and UQH2/UQ 
isopotential groups that operate at -270 mV and +20 mV respectively (63) and have been identified 
in Figure 1.5. ROS producing enzymes within the NADH/NAD+ isopotential group include 
complex I, PDH OGDH, 2-oxoapidic acid dehydrogenase complex (OADH), and the branched 
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chained 2-oxoadipic acid dehydrogenase complex (BCOADH). In complex I, there are 2 sites of 
ROS production. At site IF, electron transfer from the 2-electron carrier FMNH2 to the 1-electron 
Fe-S clusters within the complex provides an opportunity for electron escape. This is also true for 
electron transfer from the Fe-S clusters to the 2-electron carrier UQH2 in the MIM site IQ (64). 
ROS production by the 2-oxoacid dehydrogenase complexes occurs during electron transfer from 
the E2-bound dihydrolipoate to FAD and finally NAD+. The UQH2/UQ isopotential group 
includes complex III, complex II, GAPDH, ETFQO, and DHODH. Electron transfer through the 
ETC must inevitably pass through complex III. As previously discussed, electron transfer through 
complex III involves the formation of a UQ•- radical intermediate formed in the IIIQo site. This 
radical formation offers an avenue for premature electron escape to oxygen (65). ROS production 
by complex II requires an electron source in addition to oxygen access to the flavin site (63). 
Indeed, it has been demonstrated that complex II accounts for a significant amount of ROS in 
cardiac mitochondria challenged with ischemia-reperfusion injury (66). GAPDH, ETFQO, and 
DHODH each transfer electrons directly to the quinone pool. ROS production by these sites is 
minimal under physiological circumstances. GADPH has been shown to act as a significant source 
of ROS when the ETC is inhibited in the presence of high amounts of glycerol-3-phosphate (63). 
The rate of ROS produced by ETFQO was recorded through inhibition of ROS by complex I, II, 
and III with the addition of rotenone, malonate, and myxothiazol respectively with acylcarnitine 
supplementation (63).  
Complexes I and III have long been considered the major producers of ROS in 
mitochondria due to the maximum ROS producing capacity of these sites overshadowing that of 
other sites. However, the rates of ROS production from the 12 sites differ as a function of the 
concentration of the ROS producing enzyme, nutrient type and concentration, and O2 availability. 
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It has been demonstrated and recently confirmed by the Mailloux laboratory that OGDH and PDH 
have the capacity to produce approximately 4 and 8 X more ROS than complex I in skeletal muscle 
mitochondria (67–69). Furthermore, the stoichiometry of complexes of the ETC and Krebs cycle 
enzymes can differ between cell types. Our laboratory has found that the hierarchy for ROS 
production in liver mitochondria is complex III > OGDH >> PDH > complex I (69). On the other 
hand, complex I and complex II serve as the major locations of ROS production in cardiac 
mitochondria (66, 69, 70). Liver mitochondria are a more potent source for ROS overall and 
skeletal muscle mitochondria can adjust how much ROS is made and which sites generate it in 
response to rest or exercise (71).  Currently, our laboratory has also looked at sexual dimorphisms 
in mitochondrial performance. Past research has demonstrated that mitochondria isolated from 
female mice demonstrate increased basal respiration and increased capacity to burn fatty acids 
(72). Unpublished data from our laboratory demonstrate decreases in ROS production in 
mitochondria isolated from female mice.     
1.3 Antioxidant defense systems 
The dichotomy of mitochondrial ROS in cellular systems discussed previously mandates 
that considerable restriction is enforced to control ROS levels. For this reason, antioxidant defense 
systems exist to prevent excessive accumulation of ROS and strike a balance that promotes 
coordination between mitochondrial and cellular function while preventing oxidative damage and 
deregulation of essential biological systems. These systems are outlined in Figure 1.6  
  The activity of the SOD enzymes has been discussed above. They catalyze the conversion 
of O2
•- to O2 and H2O2 in the following reaction: 
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Equation 1.3: SOD activity 
   2O2
•- + 2H+     →  H2O2 + O2  
     SOD (1/2) 
As a result of the superb efficiency of the SOD enzymes, H2O2 has been acknowledged as the 
major ROS produced by mitochondria. H2O2 clearance can be mediated by catalase, which 
primarily operates within peroxisomes but can also be found to a lesser extent in the cytoplasmic 
and extracellular environment (73). Recent evidence has also demonstrated catalase occurs in liver 
and cardiac mitochondria (74, 75). This enzyme catalyzes the conversion of H2O2 to H2O and O2 
in the following reaction: 
Equation 1.4: Catalase activity 
  2H2O2      →  2 H2O + O2  
   Catalase 
Catalase quenches H2O2 in the absence of NADPH. Additionally, catalase dismutates H2O2 
only when it is high in concentration (high nM to low µM). However, it displays low affinity when 
H2O2 levels are maintained at physiological levels (76, 77). Maintenance of steady-state H2O2 
levels in and outside of mitochondria is mediated by the NADPH-dependent antioxidant defenses, 
the thioredoxin (TRX) and the glutathione (GSH) systems. TRX works in unison with 
peroxiredoxin (PRX) for the clearance of H2O2 mediated by the  PRX3 isozyme, as well as lipid 
hydroperoxides, mediated by the PRX5 isozyme (78). PRX is a homodimer with each monomer 
organized in a head-to-tail fashion. Each PRX monomer contains a catalytic peroxidatic cysteine 
(Cysper) and resolving cysteine (Cysres). Hydrogen peroxide clearance begins when Cysper is 
oxidized by H2O2 forming a sulfenic acid (SOH) (79). The SOH group is then resolved by an 
adjacent Cysres forming a disulfide bridge between the two monomers. The disulfide bridge is then 
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reduced through a thiol disulfide exchange reaction with TRX2, regenerating active PRX3 or 5. 
Oxidized TRX2 is then reduced by thioredoxin reductase-2 (TR2) and NADPH (79).  
 GSH is a tripeptide consisting of glycine, cysteine, and glutamate. The γ-carboxy group in 
glutamate is required to form the amide bond with cysteine, a unique feature that renders GSH 
resistant to degradation by peptidases. GSH synthesis occurs primarily in the cytosol of 
hepatocytes and must be transported into the mitochondria (80). Glutamate and cysteine are bound 
by γ-glutamylcysteine synthase followed by the addition of glycine by glutathione synthase (81). 
Biosynthesis is dependent on the availability of cysteine. GSH mediated degeneration of H2O2 is 
catalyzed by glutathione peroxidase 1 (GPx1) and results in dimerization and disulfide bond 
formation generating glutathione disulfide (GSSG). This is achieved using a selenocysteine 
residue localized in the active site of GPx which is oxidized to a selenic acid by H2O2. Glutathione 
then binds to GPx, forming a glutathionyl-selenic acid intermediate which is then resolved by a 
second GSH molecule producing GSSG. The GSH/GSSG ratio is a well-recognized indicator of 
the redox status of the cell and is maintained at a 100:1 ratio by the action of glutathione reductase, 
which utilizes the reductive potential of the NADPH pool in a similar manner to thioredoxin 
reduction to reduce GSSG, replenishing GSH. An isozyme of GPx, GPx4, associates with the inner 
leaflet of the MIM slowing lipid peroxide propagation (82).  
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Figure 1.6: Mitochondrial antioxidant systems 
A) Catalase found in the mitochondrial matrix mediates clearance of H2O2 B) GPX1 utilized 
GSH to clear H2O2. GSH is replenished by the action of GR. C) The thioredoxin system utilizes 
peroxiredoxin to clear H2O2. Dimerized PRX3 is reactivated through reduction by TRX2 which 
is in turn reactivated by thioredoxin reductase. D) and E) NADPH which provides the reductive 
power necessary to sustain the antioxidant systems is provided by the listed enzymes.  
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GSH is also capable of targeting by-products of oxidative damage and xenobiotic activity 
for removal from the mitochondrial matrix (82).The GSH/GSSG ratio is a well-recognized 
indicator of the redox status of the cell and is maintained at a 100:1 ratio by the action of 
glutathione reductase, which utilizes the reductive potential of the NADPH pool in a similar 
manner to thioredoxin reduction to reduce GSSG replenishing GSH. An isozyme of GPx, GPx4, 
associates with the inner leaflet of the MIM slowing lipid peroxide propagation (82). 
Mitochondrial concentrations of GSH are within 1-10 mM which allows it to act as an effective 
regulator of H2O2 levels while also carrying out additional functionality. GSH conjugation and 
protection of protein thiols, for example, is necessary to prevent excessive protein oxidation in a 
highly oxidized cellular environment. This process is known as protein S-glutathionylation and 
will be discussed in greater detail later. GSH is also capable of targeting by-products of oxidative 
damage and xenobiotic activity for removal from the mitochondrial matrix (82). 
1.4 Control of ROS production 
1.4.1 Proton leaks 
Control of ROS levels in the mitochondria and the cell can be achieved on 2 fronts; 
degradation pathways, which was discussed in the prior section, and modulation of production. 
ROS production by the discussed sites is dependent on oxygen accessibility, and the redox status 
of the ROS generating site and the concentration of the electron donating site. Two particularly 
important aspects of the control of ROS production are proton leaks and redox signaling.   
Proton leak occurs when protons are returned to the matrix, bypassing complex V. This 
can decrease the strength of the PMF, diminishing the amount of protonic back pressure on the 
respiratory chain. As a result, electrons flow more efficiently through the ETC limiting the over-
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reduction of redox centers in the respiratory complexes which diminishes the number of electrons 
that can be used to produce ROS. This phenomenon has been demonstrated using protonophores 
which chemically uncouple the proton gradient, diminishing ROS production (83, 84). In addition, 
a non-Ohmic relationship exists between membrane potential strength and the rate of ROS 
production (84). Small increases in PMF can exponentially increase ROS production while 
increasing proton return by leaks can have the opposite effect. Mild leaks can be defined as either 
basal or inducible. Basal proton leak refers to the constant, unregulated movement of protons back 
into the matrix (85). This is thought to be mediated primarily by the adenine nucleotide translocase 
(ANT). The primary function of ANT is the exchange of free ADP for ATP across the inner 
mitochondrial membrane (85). This process is essential for continued and efficient ATP production 
(86). However, it was also shown that ANT can also basally leak protons and it was demonstrated 
that changes in proton conductance in mouse muscle and whole Drosophila mitochondria are 
proportional to changes in ANT expression (87). The basal leak of protons by ANT was also 
hypothesized to be associated with the opening of the mitochondrial permeability transition pore 
(MPTP) (88). In addition, recent evidence has suggested that leaks through ANT can be regulated 
by electrophiles such as 4-hydroxy-2-nonenal, a by-product of lipid peroxidation, and nitro-fatty 
acids (41).   
Most inducible proton leaks in mammalian cells are thought to be carried out by the 
uncoupling proteins (UCP). There are five UCP isozymes found in mammals and the different 
isoforms display tissue-dependent expression. UCP1, also called thermogenin, was the first protein 
discovered that siphons protons from the IMS reducing the PMF and “uncoupling” electron 
transport and the generation of ATP.  UCP1 makes up ~13% of the mitochondrial proteome in 
brown adipose tissue mitochondria and is only activated in response to cold exposure or over-
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consumption of high-calorie foods (41). UCP1 activation involves induction of the sympathetic 
nervous system and the release of norepinephrine, which subsequently activates UCP1 using the 
cAMP-signaling pathway (89). The Gibbs free energy stored in the proton gradient is used to drive 
heat production through proton return to the matrix, instead of being coupled to the biosynthesis 
of ATP. Activation of UCP1 has also been found to control how ROS is release by brown fat 
mitochondria (41). Indeed, Echtay et al observed that ROS can regulate its own production by 
activating leaks through UCP1 (90). Another study made similar observations where it was found 
that 4-hydroxy-2-nonenal has the same effect (91). Finally, recent work by Chouchani et al found 
that UCP1 can be activated through the oxidation of cysteine residues located on the last matrix 
loop region of the protein (92). UCP2 and 3 were discovered in the late 1990s and share 
approximately 60% sequence identity with UCP1 and ~30% homology with one another (89). 
UCP2 is more ubiquitously expressed in the body and is found in stomach epithelia, the 
hypothalamus, macrophages, and pancreatic β cells. UCP3, on the other hand, is almost 
exclusively found in skeletal muscle. Notably, both proteins do not couple proton leaks to heat 
generation, which is attributed to the fact that both proteins only account for ~0.1% of total 
mitochondrial proteins (an exception is β-cells) (41). Like UCP1, leaks through UCP2 and UCP3 
were also found to be regulated by ROS, specifically O2
●-, suggesting a possible mechanism for 
self-regulation of ROS production (90). This mechanism for regulation of UCP1-3 by ROS is still 
enthusiastically debated. Some have argued that activation by ROS is not physiologically relevant 
since it is abolished by physiological concentrations of GDP (2). However, despite the contentious 
nature associated with how ROS regulates leaks through UCP1-3, it is clear that UCP2 and UCP3 
fulfill some important functions. First, there is an overwhelming amount of evidence 
demonstrating that both proteins protect cells from oxidative distress. Second, it has been found 
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that regulation of cellular ROS by UCP2 and UCP3 fulfills some vital physiological functions.  In 
pancreatic islet cells, UCP2 regulates insulin and glucagon secretion through the regulation of ATP 
and ROS production (93, 94). UCP2 is also implicated in immune cell modulation of ROS 
production (95) and modulates satiety signaling in the hypothalamus. Its overexpression has also 
been associated with decreased apoptotic signaling in neuronal and cardiac mitochondria (96, 97). 
 UCP3 is expressed primarily in skeletal muscle with limited expression in cardiac and 
brown adipose tissue. The primary function of UCP3 like UCP2 is not currently known. UCP3 
expression and activity, however, are dependent on fatty acid concentrations suggesting a strong 
case for a role in fatty acid metabolism (87). UCP3 is thought to protect against obesity as well as 
insulin resistance. Indeed, increased UCP3 expression is associated with decreased weight gain, 
and Grx2 deficiency induced a 60% increase in UCP3 expression associated with decreased fatty 
acid accumulation (98, 99). Additionally, down-regulation of UCP3 is associated with insulin 
resistance that can be rescued by exercise (89).  
1.4.2 Redox switches 
Post-translational modification is a well understood dynamic of cellular control of protein 
function. Phosphorylation, for example, is a vital element in the regulation of cellular pathways 
and embodies all required properties of a functional regulatory system. These characteristics are 
reversibility, specificity, speed and an ability to respond to physiological cues. Redox variability 
within the mitochondrial matrix, because of ROS generation, can result in post-translational 
protein modification, primarily at exposed cysteine residues. Pertinent protein modifications that 
result from changes in redox balance include sulfenylation, S-nitrosylation, and S-
glutathionylation. Redox signaling is an influence of protein function as a result of changes in 
redox balance through post-translational protein modifications. Protein cysteine thiol oxidation, 
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however, is a slow nonspecific process that requires the formation of a thiolate anion (45) and, 
therefore, not all post-translational modifications fulfill the requirements for a physiologically 
relevant mitochondrial regulatory system.  
S-nitrosylation is a promising candidate for modulation of protein function. The 
conjugation and removal of NO has been shown to alter cellular and mitochondrial processes (100–
102). NO modification can inhibit complex IV activity, suggesting a possible role for S-
nitrosylation in modifying respiration (103). Additionally, TRX of the antioxidant system 
discussed previously has been shown to mediate denitrosylation reactions (104). There are no 
known enzymes that mediate nitrosylation reactions. Additionally, the lack of specificity and the 
toxicity of high NO concentrations, particularly in mitochondria where NO and O2
•- interaction 
leads to the development of peroxynitrite (ONOO-), mark S-nitrosylation as unsuitable for 
mitochondrial regulation. In the presence of high H2O2 concentrations, the thiolate anion is 
oxidized to SOH. While this process can disable protein function, very few proteins are known to 
engage in sulfenylation. The process can be reversed by sulfiredoxin (105) unless sulfinic (SO2H) 
and sulfonic acid (SO3H) residues develop as a consequence of additional subsequent oxidation 
events. Sulfinic and sulfonic acid residues are irreversible and permanently disable protein 
function. Due to the nonspecific and slow rate of sulfenylation reactions, H2O2 has lost support as 
a useful regulator of mitochondrial function. Rather, it seems to elicit damage as a consequence of 
changes in redox balance that must be quickly and efficiently repaired by other antioxidant 
systems. Indeed, initial concepts of H2O2 mediated regulation have shifted in recent years to 
suggest that S-glutathionylation, rather, is the creditable regulatory agent. Of the three, S-
glutathionylation is the only one that fulfills the requirements for a functional regulatory system. 
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As a result, it has gained much focus in recent decades as a primary regulatory tool for 
mitochondrial maintenance of homeostasis. 
1.5 Protein S-glutathionylation 
1.5.1 Spontaneous and enzymatically-driven reactions 
 Protein S-glutathionylation reactions involve the conjugation and removal of a glutathione 
moiety from a target protein. Proteins can either be modified by glutathione via spontaneous or 
enzyme-driven reactions. Spontaneous S-glutathionylation reactions usually proceed when the 
GSH/GSSG is ~1, which typically occurs during oxidative distress, as shown in Figure 1.7. 
Spontaneous protein S-glutathionylation reactions can proceed via three different pathways 
(Figure 1.8). The first involves a simple thiol-disulfide exchange reaction between cysteine and 
GSSG (42). This requires ionization of an available protein cysteine thiol, forming a highly 
nucleophilic thiolate anion which can attack the disulfide bridge in GSSG. The second reaction 
involves oxidation of protein cysteine thiolate anion by H2O2, forming SOH (42). Sulfenic acid is 
a good nucleophile which then attacks GSSG forming a protein-glutathione mixed disulfide. 
Finally, the third spontaneous reaction involves the formation of a thiyl radical on a protein 
cysteine residue resulting in its interaction with glutathione and the S-glutathionylation of a protein 
(42).  
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Figure 1.7: S-glutathionylation reactions 
Reversible S-glutathionylation occurs as a function of redox balance and GSH availability. 
Oxidation and reduction of the glutathione pool is catalyzed by glutathione peroxidases (GPX) 
and glutathione reductases (GR). 
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Figure 1.8: Spontaneous S-glutathionylation reactions. 
Spontaneous protein S-glutathionylation reactions can proceed via two different pathways. This 
includes (A) ionization and thiolate formation followed by thiol-disulfide exchange reaction 
between cysteine and GSSG or oxidation of protein cysteine thiolate anion by H2O2, forming 
SOH followed by thiol-disulfide exchange. (B) Finally, the formation of a thiyl-radical on a 
protein cysteine residue can interact with glutathione. 
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It is important to emphasize that most proteins in normal cells (e.g. not experiencing oxidative 
distress) have an equilibrium constant for S-glutathionylation (Kmix) of approximately 1 (106). 
This means that spontaneous reactions are not likely in normally functioning mammalian cells. 
Some exceptions include the protein c-Jun, which has a reported Kmix = 15 (107). In mitochondria, 
certain proteins like complex II and UCP3 are also basally S-glutathionylated. Proteins that are 
basally S-glutathionylated may have higher than normal S-glutathionylation coefficients allowing 
for their spontaneous modification.  
 Although spontaneous reactions may occur in normal cells for a few proteins, most protein 
S-glutathionylation reactions are enzymatically driven. The GRX proteins are the chief enzymes 
that drive these reactions in cells. Glutathione S-transferases have also been shown to mediate 
these reactions in the cytosol as well (108). Glutaredoxins are a family of small heat-stable thiol 
oxidoreductases that belong to the thioredoxin superfamily. The first glutaredoxin found to 
catalyze the deglutathionylation of target proteins was the cytosolic isoform, GRX1. GRX1 can 
deglutathionylate a target protein at 102-105 M-1s-1 and the rate of deglutathionylation depends on 
the pKa of the modified cysteine residues (the lower the pKa the higher the rate) (109). GRX1 
contains a thioredoxin fold comprised of 4 beta-sheets and 3 alpha-helices. The active site CXXC 
motif is localized in the first loop region and alpha helices of the protein, which is required to drive 
the first step of deglutathionylation (110). It is important to point out that TRX proteins also 
contain a CXXC motif. However, TRX isozymes are unable to carry out the deglutathionylation of 
a protein. This is because the enzymatic deglutathionylation of a protein also requires GSH. GRX1 
harbors a GSH binding motif in its C-terminus which binds and deprotonates glutathione, 
facilitating protein deglutathionylation (111). Proteins modified by glutathione also contain 
glutathionylation motifs, which are recognized and bound by GRX1. The deglutathionylation of a 
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target protein by GRX1 can occur either through a monothiol or dithiol exchange (Figure 1.9). In 
the monothiol mechanism, GSH binds to GRX1, followed by the nucleophilic attack of GSH on 
GSH. The result is GSSG formation which is reduced by GR and NADPH (112). Dithiol exchange 
involves a thiol-disulfide exchange reaction between the CXXC motif and the target protein, 
resulting in the transfer of the glutathionyl moiety to the active site of GRX1 (42). In the second 
step, glutathione anion located in the C-terminus performs a nucleophilic attack on the GRX1-
glutathione disulfide bridge, forming GSSG and a deglutathionylated GRX1 protein. GSSG is then 
reduced by glutathione reductase (42). The deglutathionylation of target proteins by GRX1 has 
been found to regulate a wide breadth of cellular functions ranging from inflammatory signaling 
to apoptosis (42).  
The mitochondrial matrix associated GRX1 homolog, GRX2, was discovered in 2001 
(113). Although it only shares ~34% homology with GRX1, GRX2 uses a very similar enzymatic 
mechanism to deglutathionylate a target protein. While GRX2 function and structure are similar 
to that of GRX1, there are many striking differences that set the two apart. Firstly, GRX2 is capable 
of mediating both forward and reverse S-glutathionylation in response to changes in 2GSH/GSSG 
ratio (114). This has not been observed in GRX1. Secondly, GRX2 has demonstrated the capacity 
to reactivate oxidized TRX2 during TR2 deactivation by oxidative distress (115). Finally, in 
contrast, to GRX1, GRX2 cannot be deactivated by oxidation. GRX2 lacks the alternate redox-
sensitive cysteines present in GRX1 that are oxidized and lead to protein deactivation. 
Alternatively, GRX2 is activated by mitochondrial O2
•- production. GRX2 exists primarily as an 
inactive dimer stabilized by a redox-sensitive Fe-S cluster [2Fe-2S]2+. Release of mitochondrial 
O2
•- results in disassembly of this Fe-S cluster and release of active GRX2 monomers (116).  
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Figure 1.9: Protein deglutathionylation by GRX1/2.  
Deglutathionylation can proceed either via a monothiol (A) or dithiol (B) mechanism.  
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The GRX2 proteins maintain a Cys-Ser-Tyr-Cys conserved active site. The 3 isozymes GRX2a, 
GRX2b and GRX2c differ in 5`splicing patterns and are differentially expressed (113). GRX2a is 
expressed predominantly in the mitochondrial matrix, while GRX2b and GRX2c are localized to 
the nucleus and are expressed almost exclusively in the testes and some cancerous cell lines (116).  
The preferred mechanism of GRX2 action is a monothiol exchange due to its high affinity for 
protein glutathione-mixed disulfides (PSSG) (117).  
1.5.2 Mitochondrial S-glutathionylation reactions  
Generation of the proton gradient in mitochondria also, in turn, results in the basification 
of the mitochondrial matrix, creating a unique environment in which thiolate ion formation is 
favored. As previously mentioned, thiolate ion formation is required for modification of the 
exposed protein cysteine thiols. In addition, cysteine thiols are the most concentrated thiol in 
mitochondria at 60 – 90 mM (118). This, coupled with GSH concentrations that fluctuate between 
1 to 5 mM and a 2GSH/GSSG redox potential of -280 to -340 mV (41), make the mitochondrial 
matrix environment prime for S-glutathionylation. These conditions increase the likelihood of 
spontaneous and enzymatically driven PSSG formation which can reverse SOH formation and 
prevent excessive irreversible oxidation to SO2H and SO3H (119) while simultaneously modifying 
protein function through conformational changes. GRX2 mediated S-glutathionylation reactions 
allow mitochondrial bioenergetics, metabolism and ROS production to be modulated in response 
to physiological changes in redox balance. They demonstrate considerable complexity as a 
regulatory system.  
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1.5.2.1 Krebs cycle and associated enzymes  
  Multiple enzymes within the Krebs cycle link S-glutathionylation and the regulation of 
metabolism and nutrient oxidation. S-glutathionylation of aconitase decreases its activity and 
protects from irreversible oxidation of Cys126 and Cys385 (53). S-glutathionylation of IDH and SCS 
also decreases their activity in response to oxidative stress (7, 120). Our laboratory has also 
recently demonstrated that Grx2 controls PDH and OGDH in liver mitochondria (68, 69). Under 
highly oxidized situations the lipoic acid residue in the E2 subunit of both enzymes is in danger of 
irreversible oxidation. S-glutathionylation of the lipoic acid residues protects them from excessive 
oxidation. S-glutathionylation of the lipoic acid residue also leads to decreased activity and ROS 
production by both enzymes (Figure 1.10). The E2 subunit is the primary site for PDH and OGDH 
S-glutathionylation; however, work conducted by our group and others has demonstrated that the 
E1 and E3 subunits can also be modified (68, 69). ROS production by both enzymes is reduced 
during forward electron flow; however, when metabolizing NADH these enzymes increase ROS 
with increased GSH concentration (45, 68, 69). Reverse electron flow can occur at physiological 
concentrations of NADH. Given the importance of these enzymes as entry points for electrons 
from a large fraction of the available carbon metabolites, these findings suggest they are a key 
point of control by mitochondrial modulations of redox balance and that Grx2 is the mediator of 
this control (68).   
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Figure 1.10: GRX 2 mediated S-glutathionylation of OGDH and PDH 
S-glutathionylation of the lipoic acid residue of the E2 subunit decreases enzyme activity while 
simultaneously reducing ROS production. 
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1.5.2.2 Oxidative Phosphorylation  
Complex I was the first identified target of Grx2 targeted S-glutathionylation in skeletal muscle 
mitochondria and is the most extensively studied. Complex I contains an assortment of 
glutathionylation sites that elicit flexible physiologically relevant responses (99, 111, 121). Grx2 
demonstrated the ability to glutathionylate or deglutathionylate complex I in response to changes 
in 2GSH/GSSG ratio (42). S-glutathionylation of Cys531 and Cys704 of NDUSF1 leads to decreased 
ROS production and decreased enzyme activity (122). Cys531 and Cys704 are very near to the 
NADH binding site and it is suggested that GSH conjugation leads to conformational changes that 
reduce NADH oxidation. It has been suggested that S-glutathionylation of the ND3 subunit of 
complex I serves as a possible method of regulation of complex I. ND3 is exposed on a transition 
from A to D configuration in response to low substrate availability (123). Oxidative modification 
Cys39 of this subunit is associated with decreased complex I activity (124). S-glutathionylation of 
the Ndufv1 in response to increased GSSG concentrations can decrease enzyme activity and 
decrease ROS production. This has been demonstrated in mitochondria isolated from cardiac 
skeletal muscle and liver tissue as well as lens epithelia (122, 125–127). In contrast, extended 
exposure to increased GSSG concentrations results in increased ROS production by the complex 
(128). Even Ndufa11 required for complex one assembly has displayed altered function as a result 
of S-glutathionylation reactions (129) 
Each of the 5 enzyme complexes of the electron transport chain are modified and 
modulated in some way by S-glutathionylation reactions in response to altered redox state in 
physiologically relevant or disease state conditions. Complex II is constitutively S-
glutathionylated at Cys90 which helps to protect it from excessive oxidation and inactivation by 
peroxynitrite and O2
•- (130). Deglutathionylation of complex II reduces activity and increases ROS 
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production suggesting that S-glutathionylation of complex II is required for its activity. Under 
oxidative stress as in dyssynchronous heart failure, the α subunits of complex V are also reversibly 
glutathionylated reducing the ATP producing capacity of mitochondria (131). Most recently, S-
glutathionylation of complex IV and III have also been demonstrated in an S. cerevisiae model 
(132).  
1.5.2.3 Proton leak  
The least contentious function of both UCP2 and 3 is their ability to modulate 
mitochondrial ROS production. Indeed, a non-Ohmic relationship exists between membrane 
potential and ROS production where small changes in membrane potential can result in drastic 
modulation of ROS production. Thus, UCP2 and 3 represent key points of control. How 
mitochondria might implement this control, however, was not known until the demonstration that 
reversible S-glutathionylation of UCP2 and 3 regulates their activity in thymocytes, promyelocytic 
leukemia cells, kidney tissue, and skeletal muscle mitochondria (133). UCP2 S-glutathionylation 
results in increased ROS production in a number of tissues (133–135). Grx2 mediated S-
glutathionylation of UCP3 at Cys25 and Cys295 is required to inhibit proton leak (133). This was 
confirmed by increased proton leak in skeletal muscle mitochondria isolated from Grx2 
haploinsufficient and deficient mice (99). Our laboratory has also demonstrated that the absence 
of Grx2 leads to constitutive s-glutathionylation of UCP3 (70, 127). As of today, the mechanisms 
of ROS mediated UCP3 deglutathionylation and activation are not yet known. There is also 
evidence to show that ANT may be a target for S-glutathionylation, introducing yet another avenue 
for S-glutathionylation dependent regulation of ROS production. Induction of chemical S-
glutathionylation was incapable of modifying UCP1 activity suggesting that UCP1 is not regulated 
in this way (136).  
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1.5.2.4 Other mitochondrial functions  
The influence of S-glutathionylation reactions extends outside the scope of mitochondrial 
bioenergetics and ROS production. Indeed S-glutathionylation reactions influence solute import 
through modulation of the mitochondrial pyruvate carrier-1 (MPC1), MPTP formation as well as 
transport by CACT. Our laboratory has recently demonstrated that S-glutathionylation of MPC1 
almost completely abolishes pyruvate transport (127).  
MPTP formation occurs in response to indicators of cellular stress such as increased 
oxidation or cytoplasmic Ca2+ release (137). MPTP formation is essential for apoptosis and 
mitophagy. Although ANT is a debated component of MPTP, it was demonstrated that S-
glutathionylation of ANT prevents pore formation, suggesting that it may play some role in 
regulating MPTP formation (138). Likewise, S-glutathionylation of cyclophilin-D prevents MPTP 
formation (139). This is strong evidence for S-glutathionylation as a mechanism of control for 
MPTP formation and, in turn, MPTP dependent apoptotic pathways.  
The regulation of CACT by S-glutathionylation is currently under debate. It was 
demonstrated that S-glutathionylation of Cys136 and Cys155 led to inhibition of CACT activity 
(140). However, our group was unable to recreate these findings (127). Still, there is a possibility 
that S-glutathionylation reactions regulate fatty acid oxidation in this way.  
Lastly, mitochondria have demonstrated the ability to modify their structure in response to 
physiological demands. Mitochondrial hyperfusion can protect from excessive oxidation through 
increased electron transfer efficiency (141, 142). Fusion processes are carried out by mitofusin 
(MTF) 1 and 2 and the autosomal dominant optic atrophy protein 1 (OAP1), each of which have 
been demonstrated to be S-glutathionylated (143, 144). S-glutathionylation of these proteins leads 
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to mitochondrial hyperfusion suggesting a role for S-glutathionylation reactions in mediating 
changes in morphology in response to acute mitochondrial stressors.  
1.6 Skeletal muscle physiology  
Muscle tissue can be separated into three groups. Smooth, cardiac and skeletal muscle can 
then be subdivided based on the structures and differences in innervation (10). Skeletal muscle is 
the most abundant of the three. It constitutes approximately 40% of the adult male’s body mass 
and 20% the body mass of adult mice. Innervation by the somatic nervous system grants voluntary 
control over skeletal muscle giving organisms a range of movement. Skeletal muscle cells consist 
of elongated multinucleated cells that are bundled together by connective tissue to create muscle 
fibers (10). Within each cell is a highly organized cytoskeleton system consisting of thick and thin 
filaments that work in unison to generate the force required for contraction. These myofibrils make 
up~80% of the contents of muscle cells and consist of myosin, the thick filaments, actin, and the 
thin filaments. Along the myofibrils, alternating Z lines and M lines arrange the actin and myosin 
fibers such that they interlock at the center of each Z-M interval. The myosin fibers extend from 
their bass at the M line while the actin filaments extend from their base at the Z line. This 
alternating pattern of Z and M lines creates an alternating pattern of dark and light bands that give 
skeletal muscle its striated appearance under the microscope. Myosin consists of large numbers of 
dimers that each contain two identical proteins containing a tail and head domain. The tail domain 
allows dimerization and formation of the myosin fiber while the head domain contains actin 
binding and ATPase activity. The actin filament acts as a “scaffold” upon which the myosin fibers 
climb to elicit contraction. Actin filaments consist of actin tropomyosin and troponin. Troponin 
and tropomyosin hold regulatory roles. When muscle is relaxed Troponin-tropomyosin and myosin 
are bound in such a way that it prevents binding of myosin to actin filaments. Ca2+ release from 
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the sarcoplasmic reticulum binds to troponin leading to a conformational change in tropomyosin 
that removes tropomyosin from the myosin binding site enabling contraction (10). 
 Once myosin is given access to the actin filaments in response to Ca2+ release from the 
sarcoplasmic reticulum, it binds and conducts what is characterized as a power stroke. Here the 
head domain bends at a 45° angle to the myosin tail domain. This effectively pulls the actin 
filaments in towards the stationary M line a small distance. During this process bound ADP and Pi 
are released. Binding of ATP to the myosin head domain reduces its affinity for actin binding and 
the myosin head releases and returns to the unbent form. Hydrolysis of this ATP molecule 
reengages the myosin head and initiates a second power stroke. This cycle repeats continuously as 
long as ATP and Ca2+ are supplied until the muscle is fully contracted. For this reason, skeletal 
muscle is rich in mitochondria which supply the large volume of ATP required to continue 
contraction. An interesting consequence of the need for ATP for myosin release from actin 
filaments is the development of rigor mortis a few hours after death. The lack of ATP production 
and the inability of the cells to efficiently remove Ca2+ leads to a steady cross bridge formed 
between the myosin heads and actin filaments leading to unyielding and unmoving muscle tissue 
(10). 
 Skeletal muscle has always been a prime target for therapeutic strategies to combat obesity 
and related disorders like diabetes and hypertension due to the fact that skeletal muscle is a major 
location of fatty acid oxidation for ATP production. Obesity has long since been attributed to a 
positive energy balance resulting from a sedentary lifestyle coupled with excessive nutrient intake. 
Indeed, the most effective treatment options for such ailments require the maintenance of a 
negative energy balance through diet and exercise. During the initial phases of exercise, fatty acid 
oxidation increases considerably in addition to decreased esterification in adipose tissue, and 
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increased uptake by skeletal muscle (145). It is important to note, however, that these therapeutic 
strategies are not always feasible and may result in different outcomes in individuals due to 
variations in genetic background (146, 147). For this reason, many are trying instead to understand 
the processes that regulate fatty acid metabolism in skeletal muscle in an attempt to identify 
pharmaceutical targets for treatment strategies (145). In this regard, skeletal muscle mitochondria 
are poised as key targets since nutrient metabolism and fatty acid metabolism is centered within 
the matrix of the mitochondria, and mitochondria have established themselves as effective 
mediators of cellular control in addition to their primary role as energy producers.  
 In both humans and mice, high-fat diets have been shown to increase H2O2 production in 
conjunction with an increased oxidative cellular environment (148). The persistence of this 
increased oxidative state leads to the development of insulin resistance. However, that is only when 
levels are chronically high. In normal muscle, ROS levels display spatiotemporal increases and 
decreases which are vital for muscle physiology (61). The subsarcolemmal and intermyofibrillar 
populations of mitochondria both increase in volume in response to exercise and are capable of 
mediating fatty acid metabolism and cell signaling (149). These mitochondria also increase ROS 
production in response to exercise. These ROS generated by skeletal muscle mitochondria have a 
biphasic relationship with muscle function. Low-level ROS production is essential for normal 
muscle force production, while excessive ROS production leads to decreased muscle force. These 
mechanisms of regulation are dependent on post-translational modification and changes in redox 
balance (61). For example, S-glutathionylation of troponin in skeletal muscle increases its affinity 
for Ca2+ and increased S-glutathionylation of titin, a constituent of M-line in muscle sarcomeres, 
increases protein elasticity. Together this leads to increased muscle contraction efficiency (61). On 
the other hand, when antioxidant defense systems are depleted, or during strenuous exercise when 
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ROS is produced faster than it can be removed muscle force is weakened substantially by the 
presence of ROS (150). Indeed, sites within the mitochondria are the most affected by protein S-
glutathionylation reactions in response to exercise (61). Multiple locations within the TCA and 
ETC are targeted for S-glutathionylation including complex II, MDH, and ATP synthase. Indeed, 
our laboratory was the first to demonstrate S-glutathionylation of complex I and inhibition of 
pyruvate uptake as a consequence of chemical inducers of S-glutathionylation (127). This 
demonstrates additional points of regulation of metabolism in response to changes in redox 
balance.  
Recent work has also demonstrated that Grx2 was required for the regulation of UCP3 
activity in skeletal muscle mitochondria. In the absence of Grx2, UCP3 remained in a 
deglutathionated state resulting in increased proton leak dependent respiration. Grx2 seems to be 
required to glutathionylate UCP3 to decrease proton leak. This represents a promising avenue for 
regulation of fatty acid metabolism since the researchers observed that these mice, deficient and 
haploinsufficient in Grx2, displayed decreased overall bodyweight, decreased lower gonadal white 
adipose tissue weight and decreased fat associated with skeletal muscle. This was associated with 
a more oxidized 2GSH/GSSG ratio and increased ROS production from skeletal muscle 
mitochondria (99) With the ever-increasing awareness of S-glutathionylation as an effective 
mediator of cell signaling and metabolic control it is essential that its possible role in the regulation 
of fatty acid metabolism be further investigated. 
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1.7 Research objectives  
The goal of this project was to assess the role of Grx2 in the regulation of fatty acid 
metabolism and ROS generation. To do this, the impact of a diet which will cause diet-induced 
obesity (DIO) on Grx2-haploinsufficient mice was investigated. Diets that induce DIO have been 
shown to increase ROS production and increase S-glutathionylation events. This model, therefore, 
provides insight into how dysregulated S-glutathionylation reactions will affect the ability of 
skeletal muscle mitochondria to respond to challenge with a diet that induces DIO. 
1.8 Hypothesis 
Decreasing Grx2 availability will protect mice from DIO by increasing muscle fuel 
metabolism through changes in the S-glutathionylation of proteins. 
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Chapter 2: Materials and methods 
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2.1 Chemicals  
Chemical Source 
100bp DNA ladder Invitrogen 
2-propanol ACP  
40% acrylamide/Bis  Bio-Rad 
Acetic acid ACP 
ADP Sigma 
Ammonium Persulphate Sigma 
Antimycin A Sigma 
Atpenin A5 Santa Cruz 
AUR Invitrogen 
BSA Sigma 
Disulfuram Sigma 
DMSO ACP 
EGTA Sigma 
GDP Sigma 
Genapin Sigma 
Glutathione assay Kit Sigma 
Glycine Sigma 
Goat anti-mouse antibody Abcam 
Goat anti-rabbit antibody Santa Cruz 
H2O2 Sigma 
HCl Thermo 
Fisher  
HEPES Sigma 
HRP Sigma 
Insulin ELISA Kit Millipore 
Sigma 
KCL Thermo 
Fisher 
KMV Sigma 
KOH Sigma 
L-Carnitine Hydrochloride Sigma 
Lammli Buffer Bio-Rad 
Luminol Thermo 
Fisher 
Malic Acid Sigma 
Mannitol Sigma 
Methanol Thermo 
Fisher 
Chemical Source 
Monobasic Potassium phosphate Sigma 
MgCl2 Sigma 
NaCl Sigma 
NADH Sigma 
NDUSF1 primary antibody Santa Cruz 
Nitrocellulose Membrane Bio-Rad 
Non-fat Dry milk  Lab scientific 
Nuclease Free water Ambion 
OGDH primary antibody cocktail Abcam 
Oligomycin Sigma 
OXHOS primary antibody 
cocktail  
Abcam 
Palmitoyl-carnitine  Sigma 
PDH primary antibody Cocktail Abcam 
Ponceau Sigma 
Pyruvic acid Sigma 
Red extract N AMP PCR kit Sigma 
Ripa buffer Sigma 
Rotenone Sigma 
SOD Sigma 
SOD2 primary antibody Santa Cruz 
Sodium Azide Sigma 
Sodium Dodecyl Sulphate Sigma 
Stable peroxide solution Thermo 
Fisher 
Subtilisin A Sigma 
Succinic Acid Sigma 
Sucrose Sigma 
SYBR safe Invitrogen 
TEMED Bio-Rad 
Triglyceride Assay kit Cedarlane 
Tris borate EDTA Thermo 
Fisher 
Trizma Base Sigma 
Tween 20  Bio-Rad 
UCP3 primary antibody Abcam 
Ultra-pure Agarose Thermo 
Fisher 
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2.2 Mouse Breeding 
Male and female Grx2+/- mice were a gift from Dr. Mary-Ellen Harper (University of 
Ottawa). Grx2+/- mice were generated using the C57BL/6N mouse strain as described in Wu et al. 
(121, 126) the physiological and metabolic characteristics of this mouse model was performed 
previously by Mailloux et al. in 2013 (99). Additional comparisons between the Grx2+/- and Grx2-
/- strains were characterized by this laboratory previously (70). Male and female mice heterozygous 
for Grx2 (Grx2+/-) were paired (age-dependent pairing) for breeding and housed at 25 ºC on a 12-
hour day/night light cycle and provided water and chow ad libitum (Teklad Global 18% Protein 
Rodent Diet, 2018). New litters were weaned at three weeks of age and then ear notched to 
determine genotype. Ear notches were stored at -20 °C.  
2.3 Administration of DIO diets 
Female mice were either kept for breeding or used in a separate study. Male Grx2+/- mice 
and wild-type (WT) littermates were fed a high-fat diet (HFD; Teklad diet TD.06415) or matched 
control diet (CD, Teklad TD.06416) ad libitum and given free access to water until 10 weeks of 
age (Table 2.1). Mouse mass, food, and water consumption were measured once a week until 10 
weeks of age. For blood glucose measurements, mice were restrained, and the hind leg extended. 
The area just above the knee was swabbed with 75% ethanol to sterilize the surface. A small 
amount of petroleum jelly was then administered, and pressure was applied to the hind leg 
proximal to the saphenous vein. An A26 gauge ½ inch needle was used to prick the exposed vein 
and then blood was collected. Glucose levels were measured using a glucose monitoring system 
glucose test meter (FreeStyle Lite®). At 10 weeks of age, mice were euthanized by cerebral 
dislocation under heavy anesthesia (5% isoflurane). Blood was collected by cardiac puncture and 
stored at -80°C for further analysis. Mice were euthanized by cervical dislocation and liver, kidney, 
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heart, skeletal muscle (pooled forelimb, hindlimb, and pectoral muscles), and abdominal fat were 
collected, dabbed to remove excess blood, and weighed. Livers were then sectioned and used for 
histological staining. Gastrocnemius muscle was also used for histological staining and remaining 
muscle was used for the isolation of mitochondria. Animals were cared for in accordance with the 
principles and guidelines of the Canadian Council on Animal Care and the Institute of Laboratory 
Animal Resources (National Research Council). All procedures using mice were approved by the 
Animal Care and Use Committee at Memorial University of Newfoundland.  
Component TD.06415: HFD TD.06416: CD 
Fat 44.8 % Kcal 10.2% Kcal 
Lard (g/kg) 195  20 
Soybean oil (g/kg) 30  20 
Protein 19% Kcal 20% Kcal 
Casein (g/kg) 245  210 
L-Cystine (g/kg) 3.5  3 
Carbohydrate 36.2% Kcal 69.8% Kcal 
Corn starch (g/kg) 85  280 
Maltodextrin (g/kg) 115  50 
Sucrose (g/kg) 200  325 
Other Metabolites - - 
Cellulose (g/kg) 58  37.15 
Mineral mix (g/kg) 43  35 
Calcium phosphate (g/kg) 3.4  2 
Vitamin mix (g/kg) 19  15 
Choline bitartrate (g/kg) 3 2.75 
 
Table 2.1: Distributed diet 
Calorie contribution of fat, protein, and carbohydrates and individual component mass in the 
high-fat diet and matched control diet obtained from Teklab global.  
2.4 Genotyping 
2.4.1 DNA extraction 
Genotyping was carried out using the Extract-N-Amp Tissue PCR kit (Sigma Aldrich) 
according to the manufacturer’s instructions. All pipette tips and Eppendorf tubes utilized in the 
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genotyping procedures were certified nuclease-free. Ear notches were first treated with 100 µL of 
extraction solution and 25 µL of preparation solution and then mixed. This mixture was incubated 
at 25 ºC for 10 minutes followed by a 3-minute incubation at 95 ºC. The mixture was allowed to 
cool and 100 µL of the neutralization solution was added to stop the reaction.  
2.4.2 Polymerase chain reaction 
Primer sequences for the Grx2 gene were produced by Integrated DNA technologies (IDT) 
and generated according to a previously published study (70). The primer sequences are as follows: 
Forward:  
5’-GAC CTA GCC TAC CAG ACT TGG CTG AAA TTT ATT C-3’ (located in intron 2) 
Reverse:  
5’-CAT AGA CAC TCT TCA CTT TCA AGC CCA CCC TC-3’ 
Neo: 
5’-CCT ACA TTT TGA ATG GAA GGA TTG GAG CTA CGG G-3’ 
 
The following solutions were added to the PCR tube containing the extracted DNA: 1 µL 
of 0.5 µM Grx2 forward primer, 1 µM of 0.5 µM Grx2 reverse primer, 1 µL of 0.5 µM Grx2 neo 
primer, 4 µL of DNA solution, 3 µL nuclease-free water and 10 µL of REDExtract-N-Amp Tissue 
PCR Kit Reaction Mixture, giving a final volume of 20 µL. Tubes were then transferred to an 
Eppendorf master cycler pro PCR System for sequence amplification. The PCR protocol is as 
follows; a 3 minute 95 ºC denaturation step followed by 30 cycles of denaturation (94 °C 30 sec), 
annealing (63°C 1 min), and extension (72°C 1 min) with a final extension (72°C for 7 min).  
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Step Process Temperature (ºC) Time (min) 
Step 1 Denaturation 95 3 
 
Step 2 (30 Cycles) 
Denaturation 94 0.5 
Annealing 63 1 
Extension 72 1 
Step 3 Final extension 72 7 
- Incubation 4 - 
 
Table 2.2: PCR protocol for the Grx2+/- Genotyping procedures. 
 
2.4.3 Gel Electrophoresis.  
PCR samples were electrophoresed in a 1.5% (w/v) agarose gel that was produced by 
heating 0.75 g of agarose powder (Fisher Scientific) in a 0.5 X Tris-Borate-EDTA (TBE) buffer 
(Fisher Scientific, made by diluting 20 µL 10 X Tris-Borate-EDTA in 340 µL of analytical water). 
Five microliters of SYBR safe DNA gel stain was added to the gel solution. The molten agarose 
solution was then poured into the mold and allowed to solidify. Once the gel had solidified, it was 
placed in a Fisher Biotech Horizontal Electrophoresis Systems gel box. Trackit 100 bp DNA ladder 
(5 µL)(Invitrogen) was added to the first lane of the gel and 10 µL of the PCR amplified DNA 
samples were added to subsequent lanes. Electrophoresis was conducted at 90 V for 40 minutes 
and imaged using the Alpha Innotech ChemiImager Ready System. WT mice produced a single 
729 base pair (bp) nucleotide sequence. Grx2-/- mice produced a bp fragment 510 bp in size and 
Grx2+/- mice contained both nucleotide sequence fragments (Figure 2.1).  
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Figure 2.1: Gel electrophoresis 
Identification of full length or truncated versions of the Grx2 gene for WT, Grx2+/- and Grx2-/- 
characterization of mice by PCR amplification and gel electrophoresis. 
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2.5 Histological analysis 
Hematoxylin and eosin (H&E) and Oil Red O staining were performed on the liver and 
muscle sections by the Memorial University of Newfoundland Histology unit. Fixed tissue was 
processed using the TissueTek 5 automated tissue processor. Using the embedding media Leica 
Blue Ribbon paraffin. Sections from paraffin embedded tissue were cut at 5µm thickness using the 
Leica microtome Leica RM2135. The slides were dried at RT and heated at 60 °C oven for 2 hours 
and stained with HE. Fresh frozen tissue for Oil Red O was embedded in VWR® Premium Frozen 
Section Compound and cut at 8 µm thickness using the cryostat LeicaCM3050S. slides were then 
stained for Oil Red O.  
2.6 Serum biochemistry 
2.7.1 Insulin levels 
A Rat/Mouse insulin ELISA kit (MilliporeSigma) was utilized for the measurements of 
blood serum insulin. Assays were conducted according to the manufacturer’s instructions. Blood 
serum samples were warmed to room temperature. The microliter assay plate containing insulin-
specific antibodies was washed with a 1X wash buffer made from the provided 10X concentrate 
of 50 mM Tris-buffered saline containing Tween-20. First, 10 µL of assay buffer containing 0.05 
M phosphosaline, (pH 7.4), 0.025 M EDTA, 0.08% sodium azide, and 1% w/v BSA was added to 
each well. Ten microliters of matrix solution were added to a blank and control well. This 
contained charcoal stripped pooled mouse serum. Ten microliters of rat insulin standards were 
added to separate wells in duplicate. The rat insulin standards contained rat insulin in assay buffer 
at 0.2, 0.5, 1, 2, 5 and 10 ng/mL, respectively. Quality controls containing rat insulin in Quality 
Control buffer were added to QC1 and QC2. Unknown samples of mouse insulin from Grx2+/- and 
WT mice were added in duplicate to separate wells. Eighty microliters of detection antibody (Pre-
 57 
titered biotinylated anti-insulin antibody) were added to each well and the plate was agitated at a 
moderate speed for 2 hours at room temperature. Buffer was then removed, and the wells were 
washed three times with 1X wash buffer. One hundred microliters of enzyme solution (pre-titered 
streptavidin-horseradish peroxidase conjugate in buffer) were added to each well and the plate was 
agitated at room temperature for 30 minutes. Wells were then washed 6 times with 1X wash buffer. 
One hundred microliters of substrate solution (3, 3’, 5, 5’-tetramethylbenzidine in buffer) were 
added to each well and the plate was agitated for 15 minutes. One hundred microliters of stop 
solution containing 0.3 M HCl were finally added yielding a yellow color. This allowed 
quantification of immobilized ab-enzyme conjugates by the activity of HRP in the presence of 3, 
3’, 5, 5’-tetramethylbenzidine. Absorbance was recorded at 450 nm and 590 nm using a 
SpectraMax M5 plate reader and the difference was used to generate a standard curve based on the 
standard rat insulin levels.  
2.7.2 Triglyceride levels 
The L-type Triglyceride M assay kit from Wako Pure Chemical industries was utilized for 
determinations of plasma triglyceride levels. Assays were conducted according to the 
manufacturer’s instructions. A standard curve was generated with increasing concentrations of 
Wako MultiCalibrator Lipids (Cat. No. 464-01601).  To separate wells 4, 8, 12, and 16 µL of the 
standard solution were added to generate 110 mg/dL, 220 mg/dL, 330 mg/dL, and 440 mg/dL 
standard preparations in duplicate. Four microliters of analytical water and the unknown samples 
were also added to separate wells in duplicate. Ninety microliters of the R1 (color A) solution were 
added to each well and mixed by gentle rotation at 37 ºC for 5 minutes. This solution contains the 
following: 
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• 50 U/mL glycerol kinase 
• 8.0 mM ATP 
• 5.6 U/mL Glycerol-3-phosphate oxidase 
• 150 U/mL Catalase 
• 0.4 mM N-(3-isopropyl)-3methoxy-5-methylaniline (HMMPS) 
• 2.0 U/mL ascorbate oxidase  
Glycerol kinase utilizes ATP to convert free glycerol to glycerol-3-phosphate which is 
subsequently converted to dihydroxyacetone phosphate coupled with the generation of H2O2 by 
the action of glycerol-3-phosphate oxidase. The H2O2 generated is neutralized to H2O by the action 
of catalase. The absorbance was measured at 600 nM using a SpectraMax M5 plate reader. This 
reading is established as the sample blank. Following this 30 µL of R2 (color B) solution was 
added to each well and mixed by gentle rotation at 37 ºC for 5 minutes. This solution contains the 
following: 
• 250 U/mL lipoprotein lipase  
• 25 U/mL Horseradish peroxidase 
• 4.6 mM 4-aminoantipyrine 
Lipoprotein lipase cleaves triglycerides generating free fatty acids and glycerol. Glycerol is once 
again converted to dihydroxyacetone phosphate by glycerol kinase and glycerol-3-phosphate 
oxidase at the expense of ATP and coupled with the generation of H2O2. HMMPS and 4-
aminantipyrine undergo condensation to form a blue pigment in the presence of HRP and H2O2. 
The absorbance is once again read at 600 nm using a SpectraMax M5 plate reader. The final 
absorbance is calculated as the difference between the two absorbances and a standard curve is 
generated to be utilized for the measurement of serum triglyceride levels.  
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2.7.3 Glutathione/Glutathione disulfide pool 
 The glutathione assay kit from Sigma Aldrich was used to assess the GSH and GSSG 
concentrations in isolated blood serum samples. Twenty-five microliters of each plasma sample 
were transferred to a new Eppendorf tube. Two hundred microliters of 5% 5-sulfosalicylic acid 
were added to each sample to deproteinize the sample. The samples were incubated at 4 ºC for 10 
minutes followed by centrifugation at 10,000 X g for 10 minutes. The supernatant was measured 
by pipetting and this value was used in future calculations. Samples and standards provided in the 
kit were loaded into individual wells of a 96 well plate in duplicate. One hundred and fifty 
microliters of working mix containing 95 mM potassium phosphate buffer, pH 7.0, 0.95 mM 
EDTA, 0.038 mg/mL (48 µM), 5,5’-dithiobis (2-nitrobenzoic acid) (DTNB), 0.115 U/mL 
glutathione reductase were added to each well and incubated for 5 minutes with agitation. 
Following this, 50 µL of the provided NADPH solution (0.16 mg/mL) were added. The GSH in 
this assay acts as a catalyst for the continuous reduction of DNTB to 5-thio-2-nitrobenzoic acid 
(TNB), a yellow substance. The absorbance is read at 412 nm using a SpectraMax M5 plate reader 
and the GSH standards were utilized to generate a standard curve. The GSH concentration in each 
sample was calculated as follows. 
Equation 2.1: Calculation of blood serum GSH concentrations 
nmoles GSH per mL of sample:  
A412/min(sample)  dilution
A412/min (1 nmole)  volume
  
  Where:  
A412/min (sample) = slope generated by sample (after subtracting the 
values generated by the blank reaction).  
A412/min (1 nmole) = slope calculated from the standard curve for 1 
nmole of GSH  
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2.7 Preparation of muscle mitochondria 
Skeletal muscle mitochondria were isolated using basic medium (BM) using the 
differential centrifugation technique as described in (127). BM buffer consisted of KCl (140 mM), 
HEPES (20 mM), ethylene glycol-bis (β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA; 1 
mM) and MgCl2 (5 mM) dissolved in analytical water (pH 7.0 with 6 N HCl). BM was then stored 
at 4 °C. On the day of experiments, muscle homogenization medium (HM) was made fresh by 
adding ATP (1 mM) and 1% (w/v) BSA to ice cold BM. For the isolation of mitochondria, all steps 
were performed on ice or at 4 °C. ATP is added to promote myofiber depolymerization and the 
release of intermyofibrillar mitochondria. BSA was included to remove contaminating fatty acids. 
Pooled muscles were first cleaned of any connective tissue or fat and then dried and weighed. 
Skeletal muscle was then minced on a Teflon watch glass and placed in 15 mL of HM containing 
1 U of the protease subtilisin A. The volume of subtilisin A added was determined using equation 
2.2 and was added to promote myofiber degradation. Homogenization was performed using the 
Potter-Elvejham method using the Variable Speed Reversible Homogenizer (Glas-Col) and 
transferred to ultracentrifuge tubes on ice. 
Equation 2.2: Calculation of amount of Subtilisin A required for muscle extraction. 
Volume of subtilisin A (1 mg/mL) = 
Muscle (g)
1
mg
mL
 × 11.7
mg
unit
 
All centrifugation steps were performed with a Thermo Sorvall RC6+Centrifuge. The homogenate 
was centrifuged at 800 X g for 9 minutes to remove nuclei and undisrupted tissue. The supernatant 
was subsequently transferred to a second tube and centrifuged at 10,000 X g for 9 minutes. The 
supernatant was discarded, the sides of the tube carefully wiped to remove any excess fat, and the 
pellet was resuspended in 1 mL of BM and incubated for 5 minutes at 4 ºC to promote myofiber 
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repolymerization. Fourteen milliliters of BM were then added to each tube and the homogenate 
was centrifuged at 800 X g to remove the myofibers. The supernatant was then collected and 
centrifuged at 10,000 X g for 9 minutes to pellet skeletal muscle mitochondria.  
2.8 Bradford Assay 
 Mitochondrial protein concentrations were estimated using the Bradford assay (Sigma 
Aldrich). After isolation, 1 µL of isolated mitochondria was diluted in 999 µL of analytical water. 
The diluted protein sample was vortexed and then 50 µL was transferred to 200 µL of Bradford 
reagent. The volume of the solution was then adjusted to 1 mL with 750 µL of analytical water. 
Two hundred microliters of this Bradford solution were transferred to 96-well plate in duplicate 
and the absorbance was measured at 595 nm using a SpectraMax M5 plate reader. Absorbances 
were compared to a standard curve prepared previously with 0, 0.125, 0,25, 0.625, 1.25, and 1.875 
mg/mL BSA.  
2.9 Mitochondrial O2●-/H2O2 Production  
The Amplex UltraRed (AUR) assay was utilized to measure the rate of O2
●-/H2O2 
production and determine which ROS generating enzymes served as high capacity sites of 
production. The rate of ROS production can be estimated by the conversion of non-fluorescent 
AUR to fluorescent resorufin in the presence of H2O2 and horseradish peroxidase (HRP). The final 
volume for all reactions in each well was 200 µL. Assays were prepared by diluting skeletal muscle 
mitochondria in BM to a final concentration of 1.5 mg/mL. For assays involving palmitoyl-
carnitine, mitochondria were first pre-incubated in the presence of carnitine (2 mM) for 5 min. 
Mitochondria were then incubated for 5 min at room temperature in the presence or absence of 
different ROS production inhibitors. Reaction chambers were then supplemented with HRP (3 
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U/mL), SOD1 (25 U/mL) AUR (10 nM). Mitochondria contain endogenous SOD1 and SOD2 
which convert O2
●- to H2O2. Exogenous SOD1 is added to reactions to ensure the full conversion 
of O2
●- to H2O2 and increase the accuracy of the assay. Exogenous SOD1 is also added to limit the 
spontaneous production of peroxynitrite, a molecule generated through reaction between O2
●- and 
nitric oxide that is known to oxidize AUR.  Reactions were then initiated by the addition of 
substrate; pyruvate (50 µM) and malate (50 µM), succinate ((50 µM), or palmitoyl-carnitine (20 
µM; note that these reactions also contained carnitine). Changes in resorufin fluorescence were 
followed at excitation/emission wavelengths (565 nm/600 nm) for 5 minutes with reads taken once 
every 30 seconds using a SpectraMax M5 plate reader. Sample rates were compared against 
standard curves generated using 0, 20, 50, 100, 200, 500, and 1000 nM H2O2.  
For inhibitor studies and to determine which ROS generating site served as the higher 
capacity enzyme for production, mitochondria were supplemented with different combinations of 
substrate and O2
●-/H2O2 generation suppressors. To examine the contributions of OGDH and the 
respiratory chain, mitochondria were supplied pyruvate/malate with the ROS suppressors KMV 
(10 mM; OGDH inhibitor), myxothiazol (4 µM; complex III inhibitor) or atpenin A5 (50 µM; 
complex II inhibitor) (68, 69, 151). To examine ROS release exclusively by the respiratory chain, 
mitochondria were supplemented with succinate or palmitoyl-carnitine/carnitine and rotenone (4 
µM; complex I inhibitor, prevents reverse electron flow), myxothiazol (4 µM), and atpenin A5 
(50µM) (68, 69). For a clear representation of the inhibitors and their targets see Figure 2.2. 
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Figure 2.2: Inhibitors  
Rotenone (complex I), KMV (OGDH), atpenin A5 (complex II) and myxothiazol (complex III) 
were utilized to identify the sources of ROS and their sites of inhibition. 
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2.10 Mitochondrial NAD(P)H levels 
The auto-fluorescence of nicotinamide groups allowed NAD(P)H levels to be measured 
simultaneously with measurement of O2
●-/H2O2 productions. It is important to note that the 
NAD(H) pool in mitochondria is substantially more oxidized than the NADP(H) pool which is 
maintained in a highly reduced state (2). As a result, changes in nicotinamide fluorescence are 
most often associated with changes in the NAD(H) pool. NAD(P)H was measured at 376 nm:420 
nm by endpoint analysis. 
2.11 Rates of Oxygen Consumption 
2.11.1Assessing the different states of respiration 
The Oxytherm Clark-type electrode was utilized to measure the rate of mitochondrial oxygen 
consumption.  Prior to assembly, all the components of the electrode were inspected for signs of 
oxidation or degradation. The O-rings, and electrode itself were rinsed in analytical water and 
dried carefully. A drop of KCl (17.5 g/ 100 mL) was placed on the center of the Platinum (Pt) 
cathode. A small segment of filter paper large enough to cover the electrode was placed on this 
drop and soaked in KCL. A segment of O2-permeant polyvinylidene difluoride (PVDF) 
membrane cut to a similar size was placed on top of the salt bridge and the small O-ring was 
placed around the Pt cathode. A large O-ring was placed around the outside of the electrode and 
the space between the two rings was filled with KCl. The area between the large and small O-
ring was filled with KCl being careful not to overflow the chamber. The electrode was tightly 
screwed into place and a stir bead was introduced to the electrode chamber. Two milliliters of 
analytical water were added to the electrode chamber and the temperature was set to 37 ºC. A 
calibration of air-saturated water was conducted with the stir bead set at 75 %.  Subsequently, a 
small spatula of sodium dithionite (Sigma Aldrich) was added to the electrode chamber and the 
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cap was placed to establish a 0% O2 concentration in the chamber. The chamber was rinsed 
thoroughly three times with analytical water to remove any remaining sodium dithionite. 
Mitochondria were then diluted to 0.2 mg/mL in the reaction chamber containing respiration 
buffer (RB). RB consisted of MESH Mannitol (220 mM), EGTA (1 mM), sucrose (70 mM) and 
HEPES (20 mM) in addition to 0.5% w/v BSA, 10 mM monobasic potassium phosphate 
(KH2PO4) and 2 mM MgCl2 in analytical water made to pH 7.4 with 6 N HCl. Once a baseline 
oxygen consumption was established, 10 µL of substrate were added to the chamber to initiate 
state 2 respiration (Figure 2.3). Substrates included pyruvate/malate (10 mM/2 mM), succinate (5 
mM), or palmitoyl-carnitine/carnitine (50 µM/2 mM). Note that mitochondria supplied with 
palmitoyl-carnitine were incubated with carnitine for 5 minutes prior to palmitoyl-carnitine 
addition. Oxygen consumption was then measured for ~1 minute. State 3 respiration was then 
stimulated by adding ADP (1 mM). Oligomycin (4 µg/mL), an inhibitor of ATP synthase was 
then added to induce state 4 respiration (proton leak dependent respiration) this rate was also 
recorded. Finally, the reaction was ended with the addition of antimycin A allowing 
identification and exemption of contaminating oxygen consumption not associated with the 
respiration (4 µM). 
2.11.2 UCP3 dependent proton leak 
The suspicion that deregulated S-glutathionylation reactions may influence UCP3 function 
in skeletal muscle mitochondria led to the utilization of GDP and genipin to assess whether any 
differences in proton leak between genotypes may be associated with differences in UCP3 activity. 
Mitochondria were introduced to the chamber in reaction buffer in the same manner as previously 
discussed. However, the proton leak assay began with the addition of oligomycin (4 mg/mL) 
followed by pyruvate/malate (10 mM/2 mM) or succinate (5 mM) to establish state 4 respiration.   
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Figure 2.3: Oxytherm assay 
Different states of respiration measured using the oxytherm Clark-type electrode as depicted. 
Substrate and ADP addition initiates state 2 and 3 respiration respectively. Oligomycin an 
inhibitor of complex V initiates state 4 or proton-leak dependent respiration. Finally, the 
respiration is hindered by the addition of antimycin A, an inhibitor of complex III.  
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The rate was taken after 2 minutes of induced proton leak followed by the introduction of GDP (1 
mM) genipin (50 µM), or a dimethyl sulfoxide (DMSO) control. Finally, reactions were concluded 
with the addition of antimycin A (4 µM).  
Finally, an S-glutathionylation catalyst disulfiram was utilized to investigate whether the 
S-glutathionylation state of the UCP3 protein was different between genotypes and diet treatments, 
and whether or not it had any effect on UCP3 mediated proton leak. Mitochondria were prepared 
at 0.2 mg/mL in reaction buffer as previously discussed. Once again proton leak was induced with 
the addition of oligomycin (4 mg/mL) followed by pyruvate/malate (10 mM/2 mM) or succinate 
(5 mM). The rate was taken after a 2-minute period of induced proton leak followed by the 
conclusion of the experiment with the addition of antimycin A (4 µM).  
2.12 Immunoblot analysis  
2.12.1 Protein and gel preparation 
Isolated mitochondria were obtained from the -80 ºC storage and allowed to thaw. Samples 
were diluted to 3 mg/mL in Radioimmunoprecipitation assay (RIPA) buffer to a final volume of 
50 mL. RIPA buffer is a lysis buffer that disrupts the mitochondrial membranes making proteins 
more accessible. This solution was added to 50 µL of Lammli buffer which reduces intracellular 
disulfide bonds denaturing proteins and gives each an overall negative charge. It also introduces 
Bromophenol blue, which acts as a marker for how far the proteins have traveled in the 
electrophoresis unit. The samples are then incubated at 100 ºC for 10 minutes. Resolving Gels 
were prepared as either 10 % SDS or 12 % SDS for protein targets > 40 kDa and < 40 kDa 
respectively. The resolving gel was prepared by the addition of 6 mL of 40 % acrylamide solution 
5 mL of 4 X Trizma/SDS pH 8.8 solution (1.5 M Trizma base, 0.4 % SDS in 100 mL) and 9 mL 
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of analytical water. To this solution 75 µL of N,N,N',N'-tetramethylethane-1,2-diamine (TEMED) 
and 25 µL of 1% (w/v) ammonium persulfate solution (APS) were added to initiate polymerization. 
Immediately after addition to the gel mold, 2-propanol was added to the surface to create a level 
gel. The stacking gel was prepared with 1 mL 40% acrylamide solution, 2.5 mL Tris/SDS pH 6.8 
solution (0.5 mM Trizma base, 0.4 % SDS in 100 mL), and 6.5 mL analytical water. Once the 
resolving gel was set, the 2-propanol was removed, polymerization in the stacking gel was initiated 
with 75 µL TEMED and 25 µL APS. The stacking gel was placed gently on top of the resolving 
gel. The combs were immediately administered, and the gel was allowed to set. 
The 1X electrophoresis buffer consisted of 200 mL of 10 X electrophoresis buffer (250 
mM Trizma base, 1920 mM glycine, and 1 % (v/v) SDS) in 1800 mL analytical water. The gels 
prepared previously were transferred to the electrophoresis apparatus (Mini-protean Tetra System- 
Bio-Rad). Twenty microliters of PageRuler Plus Pre-stained protein ladder (Fisher Scientific) and 
previously prepared samples were added to individual wells. This provides 60 µg protein to be 
probed. Electrophoresis was run at 80 V until the proteins had passed through the stacking gel 
followed by a 40-minute run at 200 V.  
 The 1X transfer buffer consisted of 200 mL methanol, 200 mL 10 X transfer buffer (500 
mM Trizma base, 380 mM glycine, and 1 % v/v SDS) in 1600 mL analytical water. During this 
time, the extra thick blotting paper (Bio-Rad), and nitrocellulose membranes (Bio-Rad) were cut 
to an appropriate size to fit the gel. The electroblotting sponge, the thick blotting paper and 
nitrocellulose membrane were all equilibrated in transfer buffer for 20 minutes. Once the 
electrophoresis was complete the gels were transferred to the Mini Trans-Blot Electrophoretic 
Transfer Cell apparatus (Bio-Rad). Protein was transferred from gels to the nitrocellulose 
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membrane for 1 hour at 120 V. The Ponceau S dye consisting 0.5 % Ponceau S, 1% Acetic acid 
made to 200 mL was used to confirm protein transfer.  
Tris-buffered saline (TBS; 1mM Trizma base and 68 mM NaCl) with 0.1% (v/v) Tween-
20 (TBS-T) was prepared and used to remove excess Ponceau S with 3 washes for 5 minutes. The 
nitrocellulose membranes were incubated in blocking solutions which contained TBS-T and 5% 
(w/v) non-fat skim milk. Blocking solution was removed with 3 5-minute washes of TBS-T 
followed by incubation with the appropriate primary antibody diluted in TBS-T + 5% (w/v) BSA 
+ 2% (w/v) NaN3. Antibodies were validated previously as in O’Brien et al and Mailloux et al. or 
through comparison of molecular weight with those of the company issued citations (68, 152). The 
membranes were probed overnight at -20 ºC with moderate agitation. Membranes were washed 3 
times for 5 minutes with TBS-T to remove any unbound primary antibody. Membranes were 
incubated for 1 hour with secondary antibody diluted in blocking solution TBS-T and 5% (w/v) 
non-fat skim milk. Membranes were washed 3 times for 5 minutes with TBS-T to remove unbound 
secondary antibody. A 1:1 Super Signal West Pico plus luminol:Enhancer at 750 µL was added to 
the surface of each nitrocellulose membrane and the results were visualized using ImageQuant 
LAS 4000 system. Band intensities were quantified using Image J. Bands were identified using 
rectangular selections maintaining a constant area throughout. The “plot lanes” command was 
utilized to identify the relative density of each band. After removing the common background 
signal the relative area of each peak was quantified using the “wand” tool. The band intensity was 
expressed as a percentage of respective loading control.  
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Primary 
Antibody 
Primary 
Antibody 
dilution 
Secondary 
Antibody 
Secondary 
Antibody 
Dilution 
Loading 
control 
Loading 
Control 
Dilution 
Loading Control 
Secondary 
Antibody 
OGDH 1/3000 Goat anti-
mouse 
1/3000 SOD 2 
 
1/2000 Goat anti-rabbit  
1/3000  PDH 1/3000 1/2000 
OXPHOS 1/3000 NDUSF1 
 
1/3000 Goat anti-mouse 
UCP3 1/1000 
 
Table 2.3: Immunoblot antibodies  
 
2.13 Data Analysis 
Graphpad Prism 6 software was utilized for all statistical analysis. All data are represented 
as the mean ± standard error of the mean (SEM) with N ≥ 4.  Two-way analysis of variance 
(ANOVA) with a Tukey’s posthoc test was employed for all experimental results with the 
exception of proton leak investigations which utilized Fisher’s LSD. No statistical analysis was 
performed for immunoblot and histological results. Statistical significance was represented as 
follows:   
 
  
Not significant P > 0.05 
* P ≤ 0.05 
** P ≤ 0.01 
*** P ≤ 0.001 
**** P ≤ 0.0001 
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3.1 Physiology and metabolic characteristics of Grx2+/- mice 
3.1.1 Impact of HFD on body and tissue mass 
To investigate the role of Grx2 in the modulation of fatty acid metabolism, we challenged 
a Grx2 haploinsofficient mouse model and WT littermates with a HFD consisting of 44.8% Kcal 
fat or a matched CD diet (10.2% Kcal fat). The successful deletion of Grx2 was confirmed by PCR 
amplification and agarose gel electrophoresis in addition to Grx2 protein expression analysis in 
both Grx2+/- and Grx2-/- mice in previous work in our laboratory (70). The Grx2 gene is 720 bp 
long, whereas the truncated version is 510 bp, allowing easy identification with PCR amplification 
and agarose gel electrophoresis (Figure 2.1). WT mice yielded a lone band at 720 bp while Grx2-
/- yielded one band at 510 bp. Samples collected from Grx2+/- mice contained both the 720 bp and 
510 bp sequences.   
The first study to investigate the whole-body effects of Grx2 deficiency demonstrated 
decreased body weight and fat mass in Grx2-/- mice fed a standard chow diet ad libitum when 
compared to WT littermates (99). This prompted us to ascertain if whole body deletion of the Grx2 
gene protected mice from DIO. For our studies, we decided to use Grx2+/- mice and WT littermates 
since rodents homozygous for this gene develop cardiac disease and hypertension as early as 6 
weeks of age (70, 99).  No differences in body weight were observed in Grx2+/- and WT mice fed 
a CD over the 7-week period (Figure 3.1 A). This is consistent with previous findings in our 
laboratory that demonstrated no difference in whole body mass between Grx2+/-, Grx2-/- and WT 
littermates (70). Interestingly, when challenged with a HFD, Grx2+/- and WT littermates displayed 
different physiological effects. WT mice saw a significant increase in body mass from 4 to 9 weeks 
of age. By contrast, Grx2+/- mice fed a HFD did not differ in mass from WT mice or Grx2+/- mice 
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fed a matched CD (Figure 3.1 A). This was not associated with any significant differences in food 
(Figure 3.1 B) or water consumption (Figure 3.1 C). 
Our observation that Grx2+/- mice fed a HFD displayed a weight gain profile that was 
similar to mice fed a CD diet prompted the measurement of the masses of various organs, including 
fat tissue. No differences in heart mass were observed between WT and Grx2+/- mice fed either 
diet (Figure 3.2 A). Mouse kidney (Figure 3.2 B) and muscle (Figure 3.2 C) mass were also 
unaffected by diet or genotype. Interestingly, WT mice fed a HFD demonstrated small but 
significant decrease in liver mass when compared to WT or Grx2+/- mice on a CD (Figure 3.3 A). 
Liver mass of Grx2+/- mice fed a HFD did not differ from WT or Grx2+/- mice on CD (Figure 3.3 
A).  WT mice on HFD had a 2-fold increase in abdominal fat mass (Figure 3.3 B). This increase 
in abdominal fat mass was absent in Grx2+/- mice fed a HFD. Indeed, the abdominal fat mass 
observed in Grx2+/- fed a high fat diet was similar to the mass of the white adipose collected from 
WT and Grx2+/- mice fed a CD (Figure 3.3 B).  
3.1.2. Loss of Grx2 prevents intrahepatic lipid accumulation 
H&E staining was performed to ascertain if the weight gain observed in WT littermates 
fed a HFD was associated with any changes in liver and muscle histology. Muscle tissue collected 
from Grx2+/- and WT littermates fed either diet displayed no visible differences (Figure 3.4 A) 
(99). H&E staining of liver sections from WT mice fed a HFD, however, revealed a high degree 
of intracellular vacuolization (Figure 3.4 B). This is in contrast to Grx2+/- mice fed a HFD, which 
displayed a staining pattern that was similar to samples collected from rodents fed a CD. It was 
then hypothesized that the vacuolization observed in samples from WT mice fed a HFD was due 
to the intrahepatic accumulation of lipids. To test this, liver sections were treated with Oil Red-O, 
which stains fat droplets a deep red color.   
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Figure 3.1: Body mass food, and water consumption measurements 
Body mass (A) and food (B), and water consumption measurements (C). Changes in mass and 
food or water consumption were measured weekly from 4-9 weeks of age. N ≧5, mean ± SEM, 
Two-way ANOVA with a Tukey’s post-hoc test. Statistics on mouse mass and water consumption 
were run on each individual week. “*” Represents a comparison to the WT control while “#” 
represents a comparison between genotypes. 
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Figure 3.2: Heart, kidney, and skeletal muscle mass 
Heart (A), kidney (B), and skeletal muscle mass (hindlimb, forelimb and pectoral) (C). N ≧5, 
mean ± SEM, Two-way ANOVA with a Tukey’s post-hoc test. 
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Figure 3.3: Liver, and abdominal fat mass 
Liver (A), and abdominal fat mass (B). N≧5, mean ± SEM, Two-way ANOVA with a Tukey’s 
post-hoc test. “*” Represents a comparison to the WT control while “#” represents a 
comparison between genotypes. 
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Figure 3.4: Hematoxilin and Eosin and Oil Red-O stains. 
H&E staining for muscle (A) and liver (B) sections and Oil Red-O staining confirm lipid droplet 
accumulation in WT mice on HFD (C) of liver sections. N = 3 
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Oil red-O staining revealed that exposing WT littermates to a HFD for seven weeks promoted 
intrahepatocellular lipid accumulation (Figure 3.4 C). By contrast, liver sections from Grx2+/- mice 
displayed a staining pattern similar to mice fed control diets (Figure 3.4 C).  
3.1.3. Effect of deleting the Grx2 gene on circulating insulin and metabolites 
DIO and intrahepatic lipid accumulation correlate with aberrant changes in circulating 
metabolite, triglycerides and insulin levels (153). . Blood glucose measurements were performed 
weekly from 4-8 weeks of ages. Blood glucose concentrations were not significantly altered by 
diet or genotype (Figure 3.5). Intriguingly, administering a HFD to WT littermates induced a ~3-
fold increase in circulating insulin, an effect not observed in Grx2+/- mice fed the same diet (Figure 
3.6 A). Circulating insulin in Grx2+/- mice fed a HFD was significantly higher when compared to 
the control groups. However, deleting the Grx2 gene significantly diminished the HFD-mediated 
increase in blood insulin levels.  Next, triglyceride levels were measured. WT littermates fed a 
HFD contained higher blood triglyceride levels when compared to Grx2+/- fed the same diet 
(Figure 3.6 B). Additionally, triglyceride levels were similar to samples collected from the control 
groups. Overall, this indicates that Grx2+/- are protected from DIO and development of insulin 
resistance and fatty liver disease, potentially through an augmented capacity to clear triglycerides.  
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Figure 3.5: Blood glucose levels  
Measured weekly from 4 to 8 weeks of age. N ≧5, mean ± SEM, two-way ANOVA with a 
Tukey’s post-hoc test was performed on each individual week. “*” Represents a comparison to 
the WT control. 
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Figure 3.6: Serum insulin and triglyceride levels  
Serum insulin (A) and triglyceride levels (B), measured at 10 weeks of age. N ≧5, mean ± 
SEM, two-way ANOVA with a Tukey’s post-hoc test. “*” Represents a comparison to the 
WT control while “#” represents a comparison between genotypes. 
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3.2 Examination of energy metabolism in Grx2+/- mice challenged with HFD.  
3.2.1 Phosphorylating and proton leak-dependent respiration are increased in Grx2+/- mice 
   Muscle plays an integral role in whole body energy homeostasis since it is a major site for 
fat combustion for the maintenance of ATP levels. The resistance of Grx2 haploinsufficient mice 
towards DIO prompted us to examine the fuel combusting capacity of skeletal muscle 
mitochondria isolated from mice fed a CD or HFD. Fuel combustion capacity was determined by 
testing state 2, 3, and 4 respiration; indexes for the health of mitochondrial bioenergetics and their 
capacity to combust fuels to support oxidative phosphorylation. Genotype and diet did not affect 
state 2 respiration in mitochondria energized with pyruvate (Figure 3.7 A). Mitochondria isolated 
from Grx2+/- mice demonstrated a 2-fold increase in state 3 respiration. This increase occurred 
both in Grx2+/- mice fed a CD or HFD. Likewise, there was a ~2-fold increase in non-
phosphorylating respiration in skeletal mitochondria energized with pyruvate isolated from Grx2+/- 
mice fed either diet (Figure 3.7 A).  
Succinate supplementation yielded similar results. State 2 respiration remained unchanged 
by diet or genotype (Figure 3.7 B). However, there was a trend for an increase in state 2 respiration 
by Grx2+/- mice metabolizing succinate. State 3 respiration was increased by 2-fold in Grx2+/- mice 
during succinate supplementation (Figure 3.7 B). This was observed in Grx2+/- mice fed either a 
CD or HFD. Likewise, there was a ~2-fold increase in proton leak-dependent respiration in skeletal 
muscle mitochondria isolated from Grx2+/- mice metabolizing succinate (Figure 3.7 B).   
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Figure 3.7: Rates of respiration. 
Different states of respiration were measured in mitochondria oxidizing pyruvate/malate (A), succinate 
(B), palmitoyl-carnitine/carnitine (C). State 3 and 4 respiration were subsequently induced by adding 
ADP and oligomycin. N ≧5, mean ± SEM, one-way ANOVA with a Tukey’s post-hoc test. “*” 
Represents a comparison to the WT control. 
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B 
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Next, the different states of respiration were assessed in mitochondria energized with palmitoyl-
carnitine, a common fuel used for fatty acid oxidation in muscle tissue. State 2 respiration was ~2-
fold higher in Grx2+/- mitochondria collected from mice fed either diet (Figure 3.7 C). 
Measurement of phosphorylating respiration revealed that mitochondria collected from Grx2+/- 
mice fed either diet displayed a ~4-fold increase in the rate of O2 consumption (Figure 3.7 C). 
Similarly, a 2-fold increase in proton leak dependent respiration was observed in Grx2+/- mice on 
CD and HFD (Figure 3.7 C).   
3.2.2 Levels of Krebs cycle linked and OXPHOS proteins in Grx2 +/- mice 
 Changes in the rates of nutrient energy metabolism can often be explained by changes in 
the expression of enzymes associated with the Krebs cycle and OXPHOS. Therefore, the relative 
abundance of the major proteins involved in nutrient metabolism was assayed by immunoblot. 
This included PDH, OGDH and complexes I-V. Here, we discovered an increase in pyruvate 
dehydrogenase expression in WT mice fed a HFD when compared to WT mice on a matched CD 
(Figure 3.8). Interestingly, Grx2+/- mice on CD and HFD demonstrated a significant increase in 
PDH expression when compared to the WT on CD, as well (Figure 3.8). On the other hand, we 
observed no changes in expression of the E1 subunit for OGDH (Figure 3.9). Using an OXPHOS 
antibody cocktail, we also probed for the different ETC subunits found in complex I-V. We 
observed no differences in the intensity for the bands corresponding to complex I (NDUFB8), 
complex II (30 kDa subunit), complex III (core protein 2), complex IV (subunit 1), or complex V 
(α subunit) (Figure 3.10). 
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Figure 3.8: PDH protein levels 
Immunoblot with skeletal muscle mitochondria using PDH antibody cocktail identifying the E1 E2 
and E3 subunits of the PDH complex (A). Densitometry analysis was performed with ImageJ analysis 
(B)(C)(D). MnSOD was used as a loading control.  
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Figure 3.9: OGDH protein levels 
Immunoblot with skeletal muscle mitochondria using Anti-OGDH antibody (A). Densitometry 
analysis was performed with ImageJ analysis (B). MnSOD was used as a loading control. 
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Figure 3.10: OXPHOS protein levels 
Immunoblot with skeletal muscle mitochondria using OXPHOS antibody cocktail (A). Densitometry 
analysis was performed with ImageJ analysis (B-F). NDUSF1 was used as a loading control. 
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3.2.3 Increase in respiration is due to higher rate of proton return through UCP3 
 As previously discussed, S-glutathionylation reactions have been shown to regulate proton 
leak through UCP3 in skeletal muscle mitochondria. Grx2 is required to deactivate leaks through 
UCP3 through the S-glutathionylation of Cys25 and Cys256 (99). This prompted us to hypothesize 
that the increase in mitochondrial respiration and fuel combustion was due, in part, to the 
maintenance of UCP3 in an active state. To probe this notion, mitochondria were treated with 
oligomycin to induce proton leak-dependent respiration followed by exposure to GDP and genipin, 
two site specific inhibitors for UCP3  (154–156). 
While metabolizing pyruvate and malate, Grx2+/- mice on CD or HFD demonstrated a ~40 
% decrease in state 4 (proton leak-dependent) respiration when challenged with GDP (Figure 
3.11). This suggests that UCP3 is responsible for the differences in proton-leak observed between 
WT and Grx2 haploinsufficient mice. To test this further, mitochondria were treated with genipin. 
(Figure 3.11). Genipin induced a significant decline in state 4 respiration (~50% and ~40%, 
respectively in Grx2+/- mitochondria collected from mice fed a CD or HFD) (Figure 3.11). A small 
decrease was also observed in mitochondria collected from WT littermates fed either diet, but this 
effect was not significant. 
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Figure 3.11: Inhibition of state 4 by genipin and GDP 
State 4 was induced with the addition of oligomycin (4 μg/ml) followed by addition of 
pyruvate/malate (10 mM/2 mM). Respiration was measured after the addition of GDP.  
Reactions were completed with the addition of 4 μM Antimycin A. N ≧4, mean ± SEM, Two-
way ANOVA with Fisher’s LSD test. “*” Represents a comparison to the WT control. 
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Next, we decided to conduct immunoblot analyses to determine if changes in leaks were 
related to differences in the availability of UCP3. There were no changes in UCP3 expression 
regardless of the diet or genotype (Figure 3.12: UCP3 protein levels). 
This result prompted us to hypothesize that the differences in leaks were related to changes 
in the S-glutathionylation status of UCP3. To test this, state 4 respiratory conditions were induced 
and then mitochondria were treated with the chemical catalyst for S-glutathionylation reactions, 
disulfiram. It is important to note that disulfiram is a non-specific catalyst that has also been found 
to inhibit complex I through S-glutathionylation (157). However, given that leaks are higher in 
Grx2+/- mitochondria, it was anticipated that we would see a much larger disulfiram effect in these 
samples. We found that disulfiram significantly inhibited state 4 respiration in WT and Grx2+/- 
mitochondria collected from mice fed either diet (Figure 3.13). However, we found that the effect 
was much larger in Grx2+/- mitochondria indicating that it contained more deglutathionylated 
proteins (Figure 3.13).   
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Figure 3.12: UCP3 protein levels 
Immunoblot with skeletal muscle mitochondrial using Anti-UCP3 antibody (A). Densitometry 
analysis was performed with ImageJ analysis (B). NDUSF1 was used as a loading control. 
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Figure 3.13:  Inhibition of state 4 by Disulfiram 
State 4 respiration was measured in mitochondria pre-incubated in 500 μM disulfiram. State 4 was 
induced with the addition of oligomycin (4 μg/ml) followed by addition of pyruvate/malate (10 mM/2 
mM).  Reactions were completed with the addition of 4 μM Antimycin A. N ≧4, mean ± SEM, Two-
way ANOVA with Fisher’s LSD test. “*” Represents a comparison to the WT control. 
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3.3 Examination of redox balance and ROS production profile of Grx2 
haploinsufficient mice challenged with HFD.  
3.3.1 Glutathione homeostasis 
 Grx2 activity is intimately linked to the redox status of the mitochondrial glutathione pool 
and previous work found that deleting the Grx2 gene alters availability of serum GSH (70, 99). . 
Additionally, changes in GSH concentration correlate with the development of DIO (158–160). 
Therefore, we examined circulating GSH and GSSG levels. Here, Grx2+/- mice showed no change 
in GSH concentrations when compared to WT littermates on CD (Figure 3.14 A). In contrast, when 
challenged with a HFD, Grx2+/- mice demonstrated a small but significant increase in GSH 
concentration. Genotype did not alter GSSG levels. Additionally, no significant change in GSSG 
concentration was observed after administering a HFD (Figure 3.14 B). A more negative redox 
potential is associated with maintenance of a high GSH/GSSG ratio, which is required for H2O2 
detoxification. Calculating the GSH/GSSG ratio revealed that the circulating glutathione pool in 
Grx2+/- mice fed a HFD was significantly more reductive (Figure 3.14 C).  
3.3.2 O2
•-/H2O2 production is increased in Grx2
+/- challenged with HFD 
 Grx2 and protein S-glutathionylation are required to decrease ROS release from several 
Krebs cycle enzymes, as well as complexes I and II  (66, 68–70, 127, 128). Therefore, the impact 
of CD and HFD on ROS release from skeletal muscle mitochondria isolated from WT and Grx2+/- 
mice was examined. The rate of O2
●-/H2O2 was first examined using mitochondria energized with 
pyruvate (50 µM) and malate (50 µM). Mitochondria isolated from the skeletal muscle of Grx2+/- 
mice demonstrated no difference in O2
•-/H2O2 production when compared to WT littermates 
(Figure 3.15 A).   
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Figure 3.14: Serum levels of GSH, GSSG and GSH/GSSG ratio.  
Serum levels of GSH (A), GSSG (B) GSH/GSSG ratio (C) were measured at 10 weeks of age. 
N ≧5, mean ± SEM, two-way ANOVA with a Tukey’s post-hoc test. “*” Represents a 
comparison to the WT control while “#” represents a comparison between diets or genotypes. 
A 
B 
C 
C D H F D
0
5 0
1 0 0
1 5 0
2 0 0
G
S
H
 (

M
)
*
# #
#
C D H F D
0
5 0
1 0 0
1 5 0
G
S
S
G
 (

M
)
W T
G rx 2 + /-
C D H F D
0
5
1 0
1 5
G
S
H
/G
S
S
G
W T
G r x 2 + /-
*
#
 94 
  
Figure 3.15: O2●-/H2O2 release from mitochondria oxidizing pyruvate/malate 
Mitochondria in the absence of inhibitors (A) and treated with KMV, atpenin A5, and 
myxothiazol oxidizing pyruvate/malate (B). N ≧5, mean ± SEM, two-way ANOVA with a 
Tukey’s post-hoc test. “*” Represents a comparison to the WT control in the absence of 
inhibitors. 
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In contrast, there was a 2-fold increase in O2
•-/H2O2 production by mitochondria isolated 
from Grx2+/- mice challenged with a HFD (Figure 3.15 A). WT mice challenged with a HFD did 
not show a significant change in O2
•-/H2O2 production (Figure 3.15 A).  
Next, we examined which ROS generating sites in the Krebs cycle and electron transport 
chain displayed the highest rates for mitochondrial O2
●-/H2O2 production. This was achieved by 
using selective inhibitors for OGDH (KMV), atpenin A5 (complex II), and myxothiazol (complex 
III). KMV, an inhibitor of OGDH, resulted in a 4-fold increase in ROS release by WT mice on 
CD. In contrast, Grx2+/- and WT mice on HFD demonstrated no significant effect on ROS 
production from skeletal muscle mitochondria (Figure 3.15 B).   
Myxothiazol which inhibits electron transfer from the quinone pool to complex III induced 
a 2-fold increase in mitochondrial O2
•-/H2O2 production in WT mice on both diets as well as Grx2
+/- 
mice on a CD (Figure 3.15 B). This increase was much more pronounced in Grx2+/- mice 
challenged with a HFD where a ~3-fold increase in ROS release was observed (Figure 3.15 B). 
Atpenin A5, an inhibitor of complex II resulted in a 2-fold increase in O2
•-/H2O2 production 
regardless of genotype or diet (Figure 3.15 B). Together, these results indicate that complex I is 
the major ROS source when mitochondria are energized with pyruvate and malate. The Krebs 
cycle, likely PDH, is also a major source of ROS in mitochondria from WT mice fed a HFD. This 
suggests the major sources for ROS during pyruvate supplementation are complex I and possibly 
complex II.  This contrasts with previous findings that suggest that complex III is a major site for 
O2
•-/H2O2 production and that PDH and OGDH can produce up to 4 x and 8 x more O2
•-/H2O2 than 
complex I when metabolizing Krebs cycle linked substrates (68, 69).  
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Next, ROS release was examined using mitochondria energized with succinate. Complex 
II feeds electrons directly into the ETC, bypassing the Krebs cycle completely. Therefore, this 
approach gave us an opportunity to estimate ROS production from the ETC only. Skeletal muscle 
mitochondria isolated from Grx2+/- mice demonstrated no significant difference from WT 
littermates (Figure 3.16 A). When challenged with a HFD, however, Grx2+/- mice demonstrated a 
3-fold increase in O2
•-/H2O2 production (Figure 3.16 A). This increase was not reflected in WT 
mice on a HFD although a trend for an increase was apparent (Figure 3.16 A).  
Next, sites for O2
●-/H2O2 production during succinate oxidation were assessed using 
rotenone, myxothiazol, and atpenin A5. Rotenone blocks reverse electron flow from complex II 
by blocking the ubiquinone binding site in complex I. Rotenone did not alter O2
•-/H2O2 production 
by skeletal muscle mitochondria regardless of diet or genotype (Figure 3.16 B). This suggests that 
complex I is not a major contributor of O2
•-/H2O2 production during succinate oxidation. 
Supplementing mitochondria with myxothiazol induced a significant increase in ROS production 
by mitochondria from both genotypes fed either diet (Figure 3.16 B). Exposing mitochondria to 
atpenin A5 resulted in the largest increase in mitochondrial O2
•-/H2O2 production regardless of 
genotype or diet. This suggests, that when succinate is being oxidized, complex II is the major 
location of O2
•-/H2O2 production in skeletal muscle mitochondria. Succinate has been shown to 
induce O2
•-/H2O2 production from complex I through reverse electron transfer (66).  
Finally, ROS release was examined using mitochondria energized with palmitoyl-
carnitine; electrons supplied by palmitoyl-carnitine are transferred directly to the electron transfer 
chain through ETFQO (Figure 1.4) allowing investigation of ROS production associated with fatty 
acid metabolism. There were no significant differences in O2
•-/H2O2 production observed between 
mice based on genotype or diet (Figure 3.17 A).   
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B 
Figure 3.16: O2●-/H2O2 release from mitochondria oxidizing succinate  
Mitochondria in the absence of inhibitors (A) and treated with rotenone, atpenin A5, or 
myxothiazol oxidizing succinate (B). N ≧5, mean ± SEM, two-way ANOVA with a Tukey’s 
post-hoc test. “*” Represents a comparison to the WT control while “#” represents a 
comparison between genotypes. 
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Figure 3.17: O2●-/H2O2 release from mitochondria oxidizing palmitoyl carnitine 
Mitochondria in the absence of inhibitors (A) or treated with rotenone, atpenin A5, or 
myxothiazol oxidizing palmitoyl carnitine (B). N ≧5, mean ± SEM, two-way ANOVA with a 
Tukey’s post-hoc test. “*” Represents a comparison to the WT control while “#” represents a 
comparison between genotypes. 
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The sites for O2
•-/H2O2 production during palmitoyl-carnitine oxidation were also assessed 
using rotenone, myxothiazol, and atpenin A5. Inhibition by rotenone did not alter mitochondrial 
O2
•-/H2O2 production regardless of diet or genotype. The case was similar for inhibition of complex 
II by atpenin A5 (Figure 3.17 B). Inhibition of complex III by myxothiazol led to a 2-fold increase 
in mitochondrial O2
•-/H2O2 production in isolated skeletal muscle mitochondria regardless of diet 
or genotype (Figure 3.17 B). Given these results, it is likely that complex I is a major location of 
ROS production during palmitoyl-carnitine oxidation. 
3.3.3 NADH levels are not significantly altered by Grx2 haploinsufficiency or HFD 
NADH is produced by multiple Krebs cycle associated enzymes and bridges electron 
transport between Krebs cycle intermediates and the ETC (Figure 1.4). It has been demonstrated 
that elevated NADH levels can induce H2O2/O2
•- production from OGDH and PDH (8, 41, 151). 
This coupled with the fact that OGDH and PDH have previously been identified as major sources 
for O2
•-/H2O2 production in liver and skeletal muscle mitochondria (67–69), means it was essential 
that NADH levels be monitored in addition to measurement of O2
•-/H2O2 production.  
Overall, NADH levels appeared to be decreased in Grx2+/- mice on the control diet when 
compared to the WT on control diet but the effect was not significant (Figure 3.18). Interestingly, 
NADH levels of the Grx2+/- mice on HFD saw similar NADH levels as WT mice on control diet. 
During pyruvate supplementation, KMV led to decreased NADH levels. This is not unexpected 
since electron transfer from the Krebs cycle relies on NADH production from OGDH, PDH, and 
IDH. Myxothiazol inhibition of complex III led to an increase in NADH levels (Figure 3.18 A). 
This was also not unexpected since inhibiting electron transfer to complex III will slow the ETC 
leading to a decreased complex I activity and increased NADH. Inhibition of complex II had no 
effect on NADH levels (Figure 3.18 A). During succinate oxidation, inhibitors rotenone, 
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myxothiazol, and atpenin A5 had no effect on NADH (Figure 3.18 B). This is not surprising since 
electron transfer to succinate does not require NADH. During palmitoyl-carnitine 
supplementation, rotenone inhibition of complex I results in an increase in NADH levels (Figure 
3.18 C). This is likely due to the fact that, during palmitoyl oxidation, NADH and acetyl CoA are 
generated.  Acetyl CoA can feed into the Krebs cycle generating additional NADH.   
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Figure 3.18: NADH levels in isolated skeletal muscle mitochondria.  
Mitochondria were treated KMV, rotenone, atpenin A5, and myxothiazol oxidizing 
pyruvate/malate (A), succinate (B), or palmitoyl carnitine and carnitine (C). N ≧5, mean ± 
SEM, two-way ANOVA with a Tukey’s post-hoc test. “*” Represents a comparison to the WT 
control while “#” represents a comparison between genotypes. 
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4.1 Summary 
The purpose of this investigation was to examine the role of Grx2 in regulating fat 
metabolism and ROS production in skeletal muscle mitochondria. To do so, Grx2 haploinsufficient 
mice and WT littermates were challenged with HFD or matched CD. A comparison of the 
physiological and metabolic characteristics of the mice was performed in addition to redox 
balance, ROS production, and bioenergetics analyses. It is important to note that while previous 
works have probed these aspects in Grx2-/- mice (70, 99), this is the first time that it has been shown 
that Grx2 haploinsufficent male mice are protected from DIO. Indeed, the body mass of Grx2+/- 
mice was unchanged when challenged with a HFD. By contrast, WT mice fed a HFD displayed an 
increase in overall body mass, hypertrophy of white adipose tissue, increased serum insulin and 
triglyceride levels, and intrahepatic lipid accumulation. Insulin resistance is an important step in 
the development of metabolic syndrome and leads to dysregulation of peripheral lipolysis 
increasing circulating fatty acids (161). Additionally, the liver plays a central role in metabolic 
homeostasis acting as a major site for lipid synthesis and storage. High-fat diets have been shown 
to lead to increased fatty acid accumulation in the liver leading to lipotoxicity and the development 
of non-alcoholic fatty liver disease (NAFLD) which can, in turn, progress to non-alcoholic 
steatohepatitis. 
The protection experienced by mice haploinsufficient for Grx2 was attributed to the 
augmentation of fuel metabolism by muscle mitochondria. Indeed Grx2+/- mice demonstrated a ~2 
to ~3-fold increase in ADP dependent respiration, as well as proton leak dependent respiration 
through UCP3 regardless of diet or substrate being oxidized. These findings are consistent with 
previous work demonstrating that UCP3 is controlled through S-glutathionylation reactions (99, 
133). Indeed, Grx2 is required to S-glutathionylate UCP3 to reduce its activity. In the absence of 
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Grx2, UCP3 is maintained in a deglutathionylated and active state leading to increased proton leak, 
which subsequently increases fuel metabolism (99). This notion is supported further by work from 
our laboratory showing that chemical S-glutathionylation catalysts can inhibit non-
phosphorylating respiration (127). Here, we utilized selective inhibitors for UCP3, GDP and 
genipin, to confirm that UCP3 is responsible for increased proton leak in Grx2+/- mice. GDP 
reduced UCP3-mediated proton leak in Grx2+/- mice but had no significant effect on WT mice. 
Genipin elicited a similar effect.  
 Grx2+/- mitochondria also exhibited an enhanced capacity to combust palmitoyl-carnitine 
to support oxidative phosphorylation. It is likely that the augmentation of fatty acid combustion is 
due to increased proton return through UCP3 to the matrix, which contributes to the maintenance 
of normal body mass when challenged with a HFD. In conjunction with increased fuel metabolism, 
Grx2+/- mice demonstrated an altered redox state and increased mitochondrial ROS. The increase 
in ROS production is likely related to the augmentation of mitochondrial fuel combustion. 
Although ROS can be dangerous, these molecules also play a vital role in normal muscle 
physiology, namely, adaptation to exercise. This is achieved through the induction of signaling 
cascades that bolster antioxidant defenses, activate muscle repair programs, and induce the 
expression of genes involved in muscle growth. Overall, this indicates that manipulating 
mitochondrial redox signals may serve as an “exercise mimetic”. 
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4.2 Pharmacotherapeutic strategies that activate proton leaks for the treatment of 
obesity. 
4.2.1 Current strategies to prevent and treat obesity 
There are a number of strategies to prevent and treat obesity including methods that 
manipulate the balance between energy intake and expenditure, surgery, behavioral modifications, 
and pharmacological interventions. While some of these interventions can be effective, they often 
suffer from significant limitations. Increased physical activity and diet restriction is still the gold 
standard in weight loss intervention since it is non-invasive and can be highly effective at 
promoting increased whole-body energy metabolism. However, such interventions can have 
highly variable outcomes. The degree of weight loss is a function of the individual’s ability to stick 
to a strict diet and exercise regimen (162) and the efficacy of altering physical activity and diet 
restriction depends on external factors such as social, economic, and cultural influences (163). 
Additionally, the effectiveness of diet and exercise is highly variable due to genetic and epigenetic 
differences, making it more difficult for individuals to lose weight or maintain new energy 
balances following weight loss.  
Bariatric surgery has seen increased favor and employment due to promising results (164).  
Current strategies include Roux-en-Y gastric bypass, sleeve gastrectomy, and laparoscopic 
adjustable gastric band. The drawbacks of these procedures stem from cost, and complications that 
result from invasive surgery, and a selection criterion that requires patients to fall within a weight 
class, usually within a Body mass index of 30-35 (165). Patients often develop infections, 
gastrointestinal bleeding and blockage, gastroesophageal reflux, and nutritional deficiencies (166).  
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Pharmaceutical strategies have multiple targets that modify appetite, nutrient uptake, and 
removal through modulation of the serotonergic, noradrenergic and dopaminergic systems. Targets 
of the serotoninergic system include serotonin 2C receptor (5-HT2C) (167), melanocortin receptor 
(MC4) agonists (168), and arcuate neuro peptide Y receptor (NPY) antagonists (169).  Targets of 
the noradrenergic system activate α1- and β2-adrenoreceptors. Other targets that influence appetite 
include the endocannabinoid system, the Y2 receptor, and the circulating hormones, glucagon-like 
peptide-1 (GLP-1), amylin and ghrelin (170–173). These interventions are effective; however, 
their adverse effects include increased blood pressure and the development of heart valvulopathy 
(174, 175). Phentermine, for example, is highly addictive and can lead to cardiovascular toxicity 
(171). 
Some intervention strategies have turned to pharmacological activation of AMP-activated 
protein kinase (AMPK). AMPK is activated by muscle contraction and signaling pathways 
initiated by its activation mediate metabolic adaptations that protect from the development of 
metabolic disorder (176). AMPK activation by metformin, leptin, and adiponectin have 
demonstrated the ability to increase insulin sensitivity, glucose transport, mitochondrial content 
and protein expression in skeletal muscle and decreased gluconeogenesis in hepatic tissue (177–
181). AMPK activation has garnered considerable interest for its potential as exercise and calorie 
restriction mimetics; however, there is much that is still not well understood.  
Lastly, there are strategies that convert white adipose tissue (WAT) to brown adipose tissue 
(BAT). Accumulation of WAT is associated with the development of obesity and related disorders 
(182, 183). WAT has functions in long term lipid storage for times of caloric need in addition to 
immune function and hormone production (183). BAT cells appear brown in color due to a greater 
number of mitochondria and reduced lipid content in comparison to WAT cells. BAT is required 
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for non-shivering thermogenesis through UCP1 activity. This action increases energy expenditure 
since fuels are burned at a high rate to support heat production through the provision of a 
protonmotive force. As a result, research is being conducted to “brown” white fat by increasing its 
mitochondrial content. Indeed, the browning of white fat correlates with increased insulin 
sensitivity and a lower BMI (182, 184). Some browning agents include beta-amino isobutyric acid, 
gamma amino butyric acid, PPARγ, and irisin (185–188). Phase II clinical trials for leptin amylin 
analogs pramlintide and metreleptin were ended due to the development of severe adverse side 
effects (189). Currently, enough information has not been gathered to make the browning of WAT 
an effective treatment option.  
4.2.2 Uncoupling strategies 
The concept of inducing proton leaks for weight loss is not new. Early anti-obesity 
therapeutic strategies utilized chemical uncoupling agents such as 2,4 dinitrophenol (DNP), 
carbonylcyanide m-chloro phenylhydrazone (CCCP), and p-trifluoromethoxycarbonylcyanide 
phenylhydrazone (FCCP). DNP was used for a greater part of the 1930s with promising results 
(190). DNP shuttles protons across the MIM, dissipating the PMF leading to a 20-30% increase in 
energy expenditure that persisted for 24 hours. Unfortunately, DNP has a narrow therapeutic 
window and thus had some dire side effects, causing cataract and death by hyperplasia at doses 
near pharmacologically relevant concentrations. Consequently, use of chemical uncouplers for 
weight loss was banned in many countries. Nonetheless, there is still a lot of interest in exploiting 
leaks to promote weight loss through the activation of the body’s genetically encoded leakers, the 
uncoupling proteins (UCPs). 
The first uncoupling protein that was discovered was UCP1, which is required for the 
induction of thermogenesis in brown fat following cold exposure (191). Thermogenesis in BAT 
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relies on the activation of proton leaks through UCP1, which is induced by norepinephrine release 
(192). Indeed, β3-adrenergic agonist can increase energy expenditure significantly, likely through 
activation of UCP1 (146). Fatty acids also modulate the activity of UCP2 and UCP3. Indeed, 
increased fatty acid availability has been demonstrated to increase UCP2 and UCP3 mRNA 
availability (193). This suggests some role for UCP2 and 3 in the regulation of fatty acid 
metabolism. Most intriguing are the number of lines that can be drawn between the previously 
discussed treatment options for obesity and the UCP2 and UCP3 proteins. The promoter for UCP2 
expression is regulated by AMPK (194) and PPARγ agonists can also lead to increased UCP3 
expression (195). Additionally, acute exercise, leptin, and β3-adrenergic agonists induce increased 
transcription of both UCP2 and UCP3 (192, 196).  
Still, the field surrounding the regulation of UCP2 and 3 and their ability to conduct protons 
has undergone great scrutiny and is entwined with controversy (197, 198). As previously 
mentioned, the mechanism by which UCP2 and 3 conduct protons across the MIM is not yet fully 
understood. The histidine pair required for UCP1 mediated proton conductance is not present in 
the UCP2 and UCP3 homologs complicating our understanding of their function (199). 
Additionally, changes in UCP2 and UCP3 expression did not correlate with changes in proton 
leak, bringing into question whether or not these proteins conduct protons (200).  This led several 
groups to ascertain if UCP2 and 3 fulfill other functions. For instance, it has been observed that 
UCP2 and 3 are capable of transferring calcium anions,  monovalent anions, fatty acids, and 
hydroperoxide anions (155, 201–203). Despite this, it has been firmly established that UCP2 and 
3 are required to stem the effects of oxidative stress. Indeed, it has also been established that UCP2 
and 3-dependent proton leak is activated by fatty acids, O2
•-, lipid peroxides and 4-hydroxynonenal 
(32, 89, 99, 204). Also, recent work has found that Ucp3 gene expression is controlled by NRF2, 
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a critical transcription factor required for bolstering cellular antioxidant defenses in response to 
oxidative stress (205). Activating UCP3 or increasing its expression also has positive metabolic 
effects. Mice overexpressing UCP3 have reduced adiposity and increased insulin sensitivity while 
UCP3-/- mice have impaired fatty acid metabolism (98, 206). This suggests a role in the regulation 
of ROS production in addition to facilitating fatty acid oxidation.  
The increased proton leak-dependent respiration observed in Grx2+/- mice in this study is 
likely associated with the activation of UCP3. Treatment of mitochondria from Grx2+/- mice with 
GDP induced a significant decrease in non-phosphorylating respiration whereas it had no effect 
on the rate of O2 consumption in samples enriched from WT littermates. This suggests that UCP3 
is more active in Grx2+/- muscle mitochondria. It is important to point out that GDP is often 
considered a selective inhibitor for UCP3. Indeed, the structure of UCP2 in the presence of GDP 
has been determined using nuclear magnetic resonance (207). However, some studies have shown 
that GDP can also inhibit ANT, another source of leaks in mitochondria (208, 209). This prompted 
us to test the effect of genipin on non-phosphorylating respiration. Genipin was first identified as 
a membrane permeable inhibitor of UCP2 for applications in regulating insulin signaling in 
pancreatic β cells (210). Researchers demonstrated that genipin did not inhibit basal proton 
conductance by ANT and could be a specific inhibitor of UCP2 in liver and pancreatic β cells 
(210). It has also been suggested that genipin may inhibit UCP3 due to its similarity in structure 
and function to UCP2. Treatment of mitochondria from Grx2+/- mice elicited a similar effect; there 
was ~40% decrease in the rate of O2 consumption under state 4 respiratory conditions. 
Additionally, there was little to no effect on WT mitochondria. Together, these results indicate that 
UCP3 is more active in muscle mitochondria isolated from Grx2+/- mice. 
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Increased proton leak-dependent respiration as a result of Grx2 haploinsufficiency mirrors 
previous findings that characterized the physiology and ROS production profile of Grx2-/- mice 
(99) and ties together the current understanding of the functions and regulation of UCP3 in skeletal 
muscle mitochondria. In past research, while UCP3-/- mice did not demonstrate higher 
susceptibility to obesity (211), mice overexpressing human UCP3 protein demonstrated increases 
in weight loss (98). Additionally, a study using human subjects found that muscles from patients 
who had a greater rate of weight loss displayed a 51% increase in proton leak dependent respiration 
associated and a 25% increase in UCP3 mRNA expression. In previous work describing the 
characteristics of Grx2-/-, increases in proton leak were attributed to the maintenance of UCP3 in 
a deglutathionylated state (99). Here, we also found the increase in leaks in muscle mitochondria 
from Grx2+/- mice was associated with the deglutathionylation of UCP3. Indeed, treatment of 
mitochondria with the S-glutathionylation catalyst disulfiram induced a profound decrease in state 
4 respiration in WT and Grx2+/- mitochondria. However, the effect was significantly larger in 
Grx2+/- mitochondria. Note that disulfiram is a non-specific S-glutathionylation catalyst, and it is 
thus not surprising that it inhibited respiration in WT and Grx2+/- mitochondria. Indeed, in a 
previous study published by our group, it was found that disulfiram inhibited respiration in muscle 
mitochondria from C57BL6N mice through the S-glutathionylation of NDUFS1, a subunit 
required for complex I activity (127).  However, it is worthwhile to point out here there was a stark 
difference in the effect between WT and Grx2+/- mitochondria, with the latter being suppressed by 
an additional ~40%, a decrease in state 4 respiration that was also observed with mitochondria 
treated with GDP or genipin. Taken together, these results indicate that the deglutathionylation of 
UCP3 and the resulting increase in proton leak-dependent respiration is, in part, responsible for 
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the increase in mitochondrial fat combustion in muscles from Grx2+/-, which likely contributes to 
its resistance to DIO.  
4.2.3 Altered S-glutathionylation reactions influence fuel metabolism 
Under normal physiological conditions, mitochondria respond to nutritional and 
physiological cues that dictate the metabolism of the favored substrate for any given condition. In 
obese individuals there exists inflexibility and impaired fuel switching capacity, which is referred 
to as metabolic gridlock (212). It is hypothesized that excessive competition between substrates 
leads to mitochondrial indecision leading to acyl-carnitine accumulation, the over production of 
ROS, and lipid and protein damage. Antioxidant systems help to alleviate substrate competition 
through cysteine modification and the regulation of various enzymes involved in nutrient 
metabolism, resulting in the control of metabolic flux and bioenergetics  (212). Metabolic diseases 
are associated with alterations in redox buffering capacity and the inability to sustain the 
spatiotemporal flexibility of cellular redox signaling (148). Indeed, preservation or restoration of 
mitochondrial redox buffering networks and signals have been suggested to serve as a means of 
treating metabolic diseases such as obesity by alleviating metabolic gridlock  (148, 212).  
A critical observation made in this study was that there was an increase in both state 3 and 
state 4 respiration in mitochondria oxidizing either Krebs cycle linked substrates, succinate, or 
palmitoyl-carnitine. As noted above, this increase in mitochondrial fuel combustion is related, in 
part, to deglutathionylation and activation of UCP3. However, induction of leaks through UCP3 
cannot be the only factor driving this increase in fuel oxidation. Outside of UCP3, there are 
multiple S-glutathionylation targets associated with the respiratory chain and nutrient metabolism 
that could explain this increase in respiration. The first is complex I, which our group recently 
identified as a target of S-glutathionylation in muscle mitochondria (70, 157). Indeed, it was found 
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that the disulfiram induced decrease in state 3 respiration in mitochondria oxidizing pyruvate was 
associated with the S-glutathionylation of NDUFS1, a key subunit required for the catalytic 
activity of complex I (70). Previous studies have shown that modifying this subunit with 
glutathione decreases the activity of complex I (114, 152). Moreover, the S-glutathionylation of 
NDUFS1, due to defective Grx2 activity, has been associated with the development of heart 
disease and cataracts (121, 152). This is associated with a ~50% drop in mitochondrial ATP output, 
demonstrating that the reversible glutathionylation of complex I plays a vital role in regulating 
bioenergetics (152). A recent study also found that complex I is a target for S-glutathionylation 
during fatiguing muscle contraction and relaxation (61). In particular, Cys125 and Cys142 of NADH 
dehydrogenase flavoprotein 1 (NDUFV1), a well-known target for S-glutathionylation, was found 
to be modified (61). Therefore, although not measured here, it is likely that complex I is in a 
deglutathionylated state in Grx2+/- mitochondria, promoting increased respiration and fuel 
combustion. 
Outside of complex I, there are other important targets for S-glutathionylation in 
mitochondria that can alter rates of fuel combustion and respiration. For example, we recently 
discovered that mitochondrial pyruvate carrier is also a target for S-glutathionylation in muscle 
(127). In this case, induction of S-glutathionylation inhibits pyruvate uptake while 
deglutathionylation has the opposite effect (127). Another important target for S-glutathionylation 
is carnitine/acyl-carnitine carrier, which is required to facilitate the uptake of fatty acids for beta-
oxidation. Glutathionylation inhibits the antiport of acyl-carnitine and carnitine, an effect that is 
reversed by exogenous GRX1 (140). It is also important to point out that Kramer et al found that 
several complex II subunits as well as ATP synthase α-subunit and ANT were also targets for S-
glutathionylation in muscle during fatiguing exercise (61).  Glutathionylation of ATP synthase has 
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been documented to decrease its activity and prolonged modification is associated with metabolic 
dysfunction and heart disease (213). Therefore, it is also possible that maintenance of these 
proteins in a deglutathionylated state may also facilitate the high rates of fuel combustion observed 
in Grx2+/- muscle mitochondria. 
The increase in respiration in Grx2+/- mitochondria oxidizing pyruvate or palmitoyl-CoA 
also indicates that the glutathionylation state of Krebs cycle and fatty acid oxidation enzymes may 
also be altered. Candidates include PDH and OGDH, which have both been demonstrated to be 
important targets for S-glutathionylation in multiple tissues (70, 112, 214). Protein S-
glutathionylation of the E2 subunits of PDH and OGDH plays a vital role in regulating 
mitochondrial ROS production by blocking electron transfer from the E2 to the E3 subunits  (68, 
70). The trade-off is a decrease in the activity of both enzyme complexes. Our group has also 
shown for the first time that Grx2 is integral for facilitating the reversible S-glutathionylation of 
PDH and OGDH in liver and heart (70). Additionally, oxidation of mitochondrial redox buffering 
networks also compromises PDH activity in permeabilized muscle fibers, which has been linked 
to diet-induced obesity and insulin resistance (215). In this particular study, it was postulated that 
the alteration in PDH activity was related to its protein S-glutathionylation (215). Therefore, it is 
anticipated that both complexes may be maintained in a deglutathionylated state facilitating 
increased fuel combustion in mice heterozygous for Grx2. It is also important to note here that 
partial loss of Grx2 in this study induced an increase in PDH expression. This could also account 
for the increase in fuel combustion. Although PDH also increased in WT mice fed a HFD, it is 
likely that most of it is in a glutathionylated state, which would be consistent with previous 
observations made by our group (70). This would mean that in Grx2+/- mitochondria, PDH is more 
deglutathionylated rendering it more active thereby facilitating higher rates of fuel combustion. 
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Kramer et al also identified a number of S-glutathionylation targets involved in nutrient 
metabolism in muscle mitochondria (61). One intriguing observation made was that  ETFQO was 
a target for S-glutathionylation in muscle (61). Fatty acid oxidation enzymes are known to undergo 
S-nitrosylation but to our knowledge this is the first time ETFQO, a crucial component of the beta-
oxidation machinery in the matrix of mitochondria, is modified by S-glutathionylation (61, 216). 
It was recently proposed that protein S-glutathionylation serves as the linchpin for the regulation 
of mitochondrial bioenergetics in response to changes in environmental cues (112). This does 
appear to be the case since alterations in S-glutathionylation can impact mitochondrial function. 
Additionally, based on the findings presented herein, it would also seem that manipulating these 
pathways can serve as a means of increasing fuel metabolism. 
S-glutathionylation reactions also operate beyond mitochondrial metabolism to regulate 
nutrient oxidation and whole-body energy expenditure. S-glutathionylation of protein kinase A 
(PKA) desensitizes cAMP signaling reactions (217). This may explain why deregulation of S-
glutathionylation reactions demonstrates similar results to AMPK related treatment options for 
obesity. In fact, AMPK itself is S-glutathionylated and activated by GRX1 on the α and β subunits 
in response to changes in cellular H2O2 levels (218).  Understanding how AMPK activators may 
influence the S-glutathionylation reactions may provide some insight into the mode of action of 
these pharmaceutical interventions.  In skeletal muscle, S-glutathionylation reactions are necessary 
to maintain normal muscle function during fatiguing exercise. Approximately 1,290 peptides were 
glutathionylated in response to simulated fatiguing exercise (61). S-glutathionylation reactions 
regulate calcium release by the sarcoplasmic reticulum as well as calcium sensitivity of troponin. 
These S-glutathionylation reactions mediated muscle adaptation to exercise. Recent work has 
suggested that these adaptations towards exercise are facilitated, in part, through the modulation 
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of mitochondrial bioenergetics through redox signals and S-glutathionylation. Indeed, one 
intriguing study by Campbell et al showed that mitochondrial redox signals through S-
glutathionylation are integral for muscle physiology and deregulation of these pathways is linked 
to sarcopenia, an age-related degenerative muscle disorder which is characterized by dysfunctional 
bioenergetics (219). Additionally, Kramer et al found that mitochondrial S-glutathionylation 
reactions are vital in the adaption of muscle towards exercise (61). Taken together, mitochondrial 
S-glutathionylation reactions for the control of fuel metabolism are integral for normal muscle 
physiology and manipulation of these pathways may serve as a new means for promoting weight 
loss.  
4.3 Measurement and identification of mitochondrial sources of ROS 
4.3.1 Pyruvate driven ROS production in skeletal muscle mitochondria. 
Previous work with Grx2-/- mice demonstrated elevated ROS production in mitochondria 
isolated from liver but not skeletal muscle when compared to WT littermates (99). This observation 
was reversed with the addition of dithiothreitol. However, measurement of ROS production by 
mitochondria in this particular study was done using dihydrodichlorofluorescein diacetate, which 
is now known to be a non-specific fluorescent probe for the measurement of cell free radicals 
(220). Additionally, dichlorofluoresceins do not detect hydrogen peroxide. To avoid this pitfall in 
the present study, we used Amplex UltraRed to measure the rate of hydrogen peroxide production 
by skeletal muscle mitochondria isolated from WT and Grx2+/- mice fed either a HFD or CD. In 
this study, mitochondria isolated from Grx2+/- mice only demonstrated elevated levels of ROS 
production when mice were challenged with a HFD. This is consistent with past research 
demonstrating that increased fatty acid availability can lead to increased O2
•- production.  
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Mitochondria are quantifiably the most important sources of ROS in most mammalian cells 
(221). Although ROS are dangerous to cells at high levels, short bursts in H2O2 production by 
mitochondria fulfill important cell signaling functions. Indeed, ROS are important for normal 
muscle physiology, a characteristic that is underscored by the fact that myocytes rely on multiple 
H2O2 in and outside of mitochondria for adaptation and contraction. For instance, it was recently 
found that bursts in ROS release from mitochondria play an integral role in muscle repair following 
injury (222). In skeletal muscle in particular, mitochondrial ROS and S-glutathionylation reactions 
are necessary for normal muscle force production (61, 127). Additionally, H2O2 has been shown 
to be vital for adaptation to exercise which includes bolstering antioxidant defenses and inducing 
muscle growth and myocyte proliferation (216). In this study, we found that mitochondria from 
Grx2+/- mice fed a high-fat diet emit more ROS in comparison to WT mice treated with either diet. 
Although speculative at this point, it may be that the manipulation of mitochondrial redox signals 
may serve as an “exercise mimetic” through the promotion of increased ROS production. This type 
of response would demand that skeletal muscle bolster antioxidant defenses to help buffer the 
increase in mitochondrial ROS release. In the present study, we did find that when fed a HFD, 
Grx2+/- mice likely demonstrated augmentation of the biosynthesis of GSH which increases the 
GSH/GSSG. This indicates that decreasing the Grx2 avaialability may activate the NRF2 signaling 
cascade to increase the expression of antioxidant genes. Indeed, recent work has found that 
manipulating mitochondrial glutathione buffering systems leads to the stabilization of NRF2 and 
the induction of antioxidant defense gene expression through increased ROS production (223). 
Furthermore, Campbell et al recently demonstrated that preservation of mitochondrial redox 
signals in the muscles of aged mice facilitates mitochondria-to-cell communication for the 
maintenance of muscle contractility (219). Furthermore, manipulation of the redox state of 
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glutathione pools protects rodents from diet-induced obesity (224). Taken together, we propose 
that manipulating mitochondrial redox environments and altering protein S-glutathionylation 
patterns may serve as a means of promoting an exercise effect in muscles, which could potentially 
be exploited for the prevention or reversal of weight gain. 
One critical issue that needs to be addressed is our contradictory observation that 
mitochondria from Grx2 haploinsufficient mice produce more ROS but also have a higher rate of 
non-phosphorylating respiration (e.g. proton leaks). An increase in proton leaks is often viewed as 
a countermeasure towards increased ROS production. For instance, an increase in leaks diminishes 
protonic back pressure on the respiratory chain augmenting electron flow through the chain which 
in turn diminishes the number of electrons available for ROS production (99). Numerous studies 
have demonstrated that leaks are integral for diminishing ROS release from the electron transport 
chain (90, 136, 146, 225, 226). However, the relationship between mitochondria and ROS 
production is far more complicated and is not simply a “tug-of-war” between protonic pressure 
and the rate of electron flow through the ETC. For instance, mitochondria contain 16 ROS sources, 
12 of which are associated with nutrient metabolism and respiration (227–229). Secondly, these 
individual sites of production are subjected to heavy regulation by allosteric modulators and 
covalent modifications, which can alter the rate of production. The rate of production also depends 
on substrate availability, type, and the concentration of the electron donor (e.g. the amount of 
enzyme) (112). Increased fuel metabolism has also been linked to higher rates of ROS production 
in muscle (230). Finally, it is now accepted that protonmotive force may not be a major determinant 
for dictating ROS production. This concept is underscored by the fact that activation of UCP1 
leads to increased ROS production (231). Indeed, leaders in the field have indicated that a direct 
relationship between mitochondrial ROS and membrane potential is not as simple as it seems 
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(227). Therefore, it is likely that the increase in ROS production is related to the augmentation in 
fuel oxidation in response to feeding mice a high fat diet. 
In the present study, we also examined which ROS source associated with fuel metabolism 
made the largest contribution to overall production. Here, we examined the rate of ROS production 
by PDH and OGDH and complexes I-III, which our group and others had previously identified as 
major sources in liver, muscle, and heart tissue (66, 68–70). First, using pyruvate and malate as 
substrates, we found that complex I was a major source of ROS. This is attributed to the 
observation that myxothiazol, which inhibits ROS production by complex III, augmented the rate 
of H2O2 production. We attribute this effect to the accumulation of electrons upstream from 
complex III. Secondly, atpenin A5 elicited a similar effect, increasing ROS production. Together, 
these findings indicate that complex I is a major site of production. We also observed that KMV, 
an inhibitor for ROS production by OGDH, also increased the rate of production, although in some 
cases the augmentation was not significant relative to the control. This indicates that complex I 
and to a lesser extent PDH are major sources of ROS in muscle mitochondria. These observations 
are in line with several studies that have found PDH and complex I are critical mitochondrial ROS 
sources. For instance, Fisher-Wellman et al demonstrated that PDH is a critical ROS supplier in 
mouse, rat, and human muscle tissue (232). Furthermore, several other studies have provided 
evidence that PDH and complex I are also major sources (68–70, 151).  
It has also been shown by Goncalves et al. that mitochondria from muscle can adopt a 
diverse ROS release profile in response to changes in substrate type and supply (227). For instance, 
the major sites of production in muscles oxidizing succinate are complexes I-III whereas when 
glutamate and malate are substrates, other sources, such as OGDH, are critical ROS generators 
(229). Here, in mitochondria oxidizing succinate, we found that complex II was the major ROS 
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source. This was made clear due to the atpenin A5 effect, which inhibits complex II by 
competitively blocking the UQ binding site. Indeed, treating mitochondria with atpenin A5 
induced a robust increase in ROS production. By contrast, rotenone had little effect indicating the 
source of ROS was generated by complex I due to reverse electron flow from succinate. 
Myxothiazol also elevated ROS production, indicating that the source was upstream from complex 
III and was most likely complex II.  
Finally, we tested which respiratory complex served as the major source of production 
when palmitoyl-carnitine was the substrate. Treating mitochondria with rotenone and atpenin A5 
elicited no change in ROS production, indicating reverse flow to complexes I and II were not 
sources during fatty acid oxidation. This is surprising since a study conducted by Perevoshchikova 
et al. found that both complexes I and II were potent sources in permeabilized rat mitochondria 
oxidizing palmitate (233). However, we did find that treatment with myxothiazol induced an 
increase in ROS production. This is intriguing since it would suggest that complex III is not a 
major source during fat oxidation either. Based on this evidence, ETFQO is the major ROS 
generator in mouse muscle mitochondria oxidizing palmitate. It is worthwhile to note that our 
group has observed that there is a strong strain effect for which ROS generating sites make major 
contributions to overall production in mitochondria (234). For example, in C57BL6N mice, 
OGDH, PDH, and complex II are important sources in liver mitochondria whereas in the 6J strain 
branched chain keto acid dehydrogenase is a major generator (234). This concept of a strain effect 
on rates of production from different enzymes may also apply to what organism is being used to 
study ROS genesis. For example, most of the studies dedicated to measuring the rate of ROS 
production from the 12 different sites associated with nutrient metabolism have been conducted 
using Sprague-Dawley rats (229). In these studies, ETFQO was characterized as a minor site. 
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However, our group has found that ETFQO is a critical source in mouse mitochondria from male 
and female mice (this study and unpublished work in a separate study). Taken together, this would 
indicate that sites of production need to be carefully considered when studying ROS release 
profiles in different model systems for human diseases.  
4.4 Conclusion and future directions 
Here we have demonstrated that S-glutathionylation reactions have a major role in the 
modulation of fat metabolism and ROS release in skeletal muscle mitochondria. 
haploinsufficiency in Grx2 granted protection from diet-induced weight gain and associated 
disorders including insulin resistance and fatty liver disease. These advantages stemmed from 
dysregulation of S-glutathionylation reactions leading to three main modifications of normal 
mitochondrial function. This included 1) increased fuel metabolism associated with dysregulation 
of enzymes and complexes of the ETC and Krebs cycle, 2) constitutive glutathionylation of UCP3 
leading to increased state 4 respiration and energy expenditure and 3) increased ROS production 
and redox buffering capacity initiating stress signaling pathways that amplify fatty acid 
metabolism and protect from metabolic gridlock. These findings introduce a new avenue for 
treating and preventing DIO through manipulation of redox signaling in skeletal muscle. However, 
further investigation is required before pharmacotherapeutic strategies can be explored. Future 
directions currently involve investigating skeletal muscle, liver and cardiac mitochondria isolated 
from Grx2+/- mice challenged with a HFD. Comparisons will be made to the WT mice on CD and 
HFD to investigate the effect of this challenge on liver and cardiac mitochondria in addition to 
investigation of the possibility of sexual dimorphism in mitochondrial regulation by Grx2.  
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